RGI-2001-003  Page 1 of 84 
Final Version  2.0 Proprietary and Confidential  06 March 2020  
CLINICAL STUDY PROTOCOL  
Protocol Title:  An Open Label, Non- Randomized Multicenter Phase 
2b, Study with a Safety Run-in to Evaluate the Safety 
and Efficacy of RGI -2001 for the Prevention of Acute 
Graft- Versus -Host Disease (aGvHD) Compared to 
Contemporary Controls in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation 
(alloHSCT)  
Protocol Number:  RGI-2001-003 
Investigational Product: RGI-2001 
IND Number/NCT Number: 102,285 / [STUDY_ID_REMOVED] 
Sponsor:  REGiMMUNE Corporation  
35-3 Nihonbashi Hakozaki- cho BRICK GATE 5F,
Chuou-ku, Tokyo 103-0015 Japan
Protocol Date and Version : Original: 18 March 2019, Version 1.0 
Amendment #1: 06 March 2020, Version 2.0 
CONDUCT  
This study will be conducted according to the protocol and in compliance with Good Clinical 
Practice (GCP) , the ethical principles stated in t he Declaration of Helsinki, and other 
applicable regulatory requirements . 
CONFIDENTIAL  INFORMATION  
This is a REGiMMUNE  Corporation document that contains confidential information.  It is 
intended solely  for the recipient  clinical investigator(s)  and must not be disclosed  to any 
other  party. This material may be used only for evaluating or conducting clinical  
investigations; any other  proposed use requires written  consent  from REGiMMUNE  
Corporation. 
 
 
  
RGI-2001-003   
Page 2 of 84 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020  
PROTOCOL APPROV AL  SIGNATU RE PAGE  
 
Protocol Title:  An Open Label, Non -Randomized Multicenter Phase 2b, Study 
with a Safety Run-in to Evaluate the Safety and Efficacy of 
RGI-2001 for the Prevention of Acute Graft- Versus- Host 
Disease Compared to Contemporary Controls in Subjects 
Following Allogeneic Hematopoietic Stem Cell Transplantation 
(alloHSCT)  
 
  
Protocol Number:  RGI-2001 -003 
  
  
  
Date : 06 March  2020  
  
   
 
 
  Date  
 
 

 
 
  
RGI-2001-003   
Page 3 of 84 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020  
INVESTIGATOR SIGNATURE PAGE  
 
Protocol Title: An Open Label, Non-Randomized Multicenter Phase 2b, Study with a Safety 
Run-in to Evaluate the Safety and Efficacy of RGI-2001 for the Prevention of Acute Graft-
Versus- Host Disease Compared to Contemporary Controls in Subjects Following Allogeneic 
Hematopoi etic Stem Cell Transplantation (alloHSCT) 
 
Date: 06 March 2020 
 
 Signature on this page assures the S ponsor that, to the best of the investigator’s knowledge, the 
affiliated Institutional Review Board (IRB) operates in accordance with the governing 
regulations, and that the investigator under stands, and agrees to conduct this study in 
accordance with the protocol and according to the Declaration of Helsinki, the Code of Federal 
Regulations on the Protection of Human Subjects (45 CFR Part 46), the  Interna tional Council 
for Harmoniz ation (ICH) E6 Guideline for Good Clinical Practice (GCP), and all applicable 
regulatory requirements. All study site personnel involved in the study will be under their 
direction and informed about the contents of this study protocol and will receive all necessary 
instructions for conducting the study in accordance with the study protocol.  
 
 
________________________________________  _______________________ Investigator’s Signature       Date  
 _______________________________________ Name (printed) 
 
 
 
 
  
RGI-2001-003   
Page 4 of 84 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020  
TABLE OF CONTENTS  
CLINICAL STUDY PROTOCOL  ..................................................................................................1  
PROTOCOL APPROVAL SIGNATURE PAGE  ...........................................................................2  
INVESTIGATOR SIGNATU RE PAGE  .........................................................................................3  
TABLE OF CONTENTS  .................................................................................................................4  
TABLE OF TABLES  ......................................................................................................................7  
TABLE OF FIGURES  .....................................................................................................................7  
1 LIST OF ABBREVIATIONS AND DEFINITIONS OF  TERMS .........................................8  
2 PROTOCOL SYNOPSIS ......................................................................................................11  
3 SCHEDULE OF ASSESSMENTS  .......................................................................................21  
4 INTRODUCTION  ................................................................................................................24  
4.1 Background ................................................................................................................24  
4.1.1  Graft Versus Host Disease ..........................................................................24  
4.1.2  CD4+Foxp3+ Regulatory T- cells ................................................................25  
4.2 Investigational Product ...............................................................................................26  
4.3 Study Rationale ..........................................................................................................26  
4.4 Summary of Nonclinical Data  ....................................................................................27  
4.5 Summary of Clinical Data  ..........................................................................................29  
4.6 Risks/Benefits  ............................................................................................................30  
4.7 Dose Regimen and Treatment Period Rationale ........................................................32  
5 STUDY OBJECTIVES AND ENDPOINTS  ........................................................................34  
6 STUDY DESIGN ..................................................................................................................36  
6.1 Safety Run-in Phase ...................................................................................................37  
6.1.1  Definition of Dose -limiting  Toxicities  ........................................................38  
6.2 Expansion Phase .........................................................................................................39  
6.3 Control Group ............................................................................................................39  
6.4 Safety Review Committee ..........................................................................................39  
6.5 Number of Sites  ..........................................................................................................39  
6.6 Number of Subjects  ....................................................................................................40  
6.7 Study Duration ...........................................................................................................40  
7 SUBJECT POPULATION....................................................................................................41  
7.1 Inclusion Criteria  ........................................................................................................41  
7.2 Exclusion Criteria  .......................................................................................................42  
7.3 Eligibility for the Control Arm ...................................................................................43  
7.4 Donor Screening .........................................................................................................43  
7.5 Withdrawal/Discontinuation from Treatment, Procedures and Study  .......................44  
7.5.1  Study Discontinuation .................................................................................44  
 
 
  
RGI-2001-003   
Page 5 of 84 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020  
7.5.2  Subjects’ Decision to Withdraw  ..................................................................44  
7.5.3  Discontinuation of Study Treatment and/or Withdrawal of Subjects 
Prior to Study Completion  ...........................................................................45  
7.6 Replacement  of Subjects ............................................................................................45  
8 STUDY DRUG  .....................................................................................................................46  
  
8.2 Packaging and Labeling .............................................................................................46  
8.3 Storage ........................................................................................................................46  
8.4 Study Drug Accountability.........................................................................................46  
8.5 Return and Disposition of Study Drug .......................................................................46  
8.6 Administration and Dosing Regimen .........................................................................47  
8.7 Randomization and Blinding ......................................................................................47  
8.8 Prior and Concomitant Medications ...........................................................................47  
8.9 Dietary  or Other  Protocol  Restrictions .......................................................................48  
8.10  Dose Modification/Treatment Cessation  ....................................................................48  
8.10.1  Safety Run-in Phase ....................................................................................48  
8.10.2  Expansion Phase ..........................................................................................48  
8.11  Management of Cytokine Release Syndrome  ............................................................49  
9 STUDY ASSESSMENTS AN D PROCEDURES  ................................................................51  
9.1 General Study Procedures ..........................................................................................51  
9.1.1  Informed Consent ........................................................................................51  
9.1.2  Demographics ..............................................................................................51  
9.1.3  Medical/Cancer/Surgical History  ................................................................51  
9.2 Efficacy Assessments  .................................................................................................52  
9.3 Evaluation of GvHD...................................................................................................52  
9.3.1  Tumor Assessment  ......................................................................................52  
  
  
  
9.4 Safety Assessments  ....................................................................................................53  
9.4.1  Marrow  Engraftment and Graft Failure  .......................................................53  
9.4.2  Dose Lim iting Toxicities .............................................................................53  
9.4.3  Adverse Events ............................................................................................53  
9.4.4  Concomitant Medications ............................................................................53  
9.4.5  Weight and Height  .......................................................................................54  
9.4.6  Physical Examinations, Vital Signs and Karnofsky Performance Status  ...........................................................................................................54
 
9.4.7  Electrocardiogram  .......................................................................................54  

 
 
  
RGI-2001-003   
Page 6 of 84 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020  
9.4.8  Clinical Laboratory Assessments  ................................................................54  
10 ADVERSE EVENTS  ............................................................................................................57  
10.1  Definitions  ..................................................................................................................57  
10.1.1  Serious Adverse Event  ................................................................................57  
10.2  Adverse Event Reporting ...........................................................................................58  
10.2.1  Laboratory Test Abnormalities  ...................................................................58  
10.2.2  Adverse Event Severity  ...............................................................................59  
10.2.3  Adverse Event Causality  .............................................................................60  
10.3  Serious Adverse Events  ..............................................................................................61  
10.3.1  Serious Adverse Events Reporting  ..............................................................61  
10.4  Reporting of Disease Progression  ..............................................................................62  
10.5  Reporting of GvHD ....................................................................................................62  
10.6  Medication Errors  .......................................................................................................62  
10.7  Pregnancy ...................................................................................................................63  
11 REGISTRATION OF CIBM TR SUBJECTS FOR TH E CONTROL GROUP  ...................64  
11.1  Selection of Control Arm Transplant Centers  ............................................................64  
11.2  Enrollment Procedure for the Transplant Subjects in the Control Arm via the 
CIBMTR  ....................................................................................................................64  
12 STATISTICS ........................................................................................................................65  
 
12.2  Demographics and Baseline Characteristics  ..............................................................65  
12.3  Analysis Population, Handling of Dropouts, and Missing Data ................................65  
12.3.1  Analysis of Efficacy Data ............................................................................66  
12.4  Suspension Rules Based on Safety (RRT, Graft Failure, and NRM)  ........................66  
13 ETHICAL AND ADMINIST RATIVE CONSIDERATION S .............................................68  
13.1  Ethics  ..........................................................................................................................68  
13.2  Compliance Statement ................................................................................................68  
13.3  Institutional Review Board  ........................................................................................68  
13.4  Informed Consent and Human Subject Protection .....................................................68  
13.4.1  Direct Access to Source Data/Source Documents  ......................................68  
13.4.2  Data Quality Control and Quality Assurance: Data Handling and 
Recordkeeping .............................................................................................69  
13.4.3  Confidentiality  .............................................................................................69  
14 FINAL STUDY REPORT AND PUBLICATION POLIC Y ...............................................70  
REFERENCES ..............................................................................................................................71  
15 APPENDICES ......................................................................................................................73  
Appendix 1  PHARMACOKINETICS (RGI -2001) AND 
PHARMACODYNAMICS SAMPLING SCHEDULE  ..............................74  

 
 
  
RGI-2001-003   
Page 7 of 84 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020  
Appendix 2  MAGIC GVHD ASSESSMENT CRITERIA  .............................................75  
Appendix 3  MODIFIED KEYSTONE CRITERIA FOR ACUTE GVHD  ....................77  
Appendix 4  NIH DEFINED DIAGNOSTIC OR DISTINCTIVE FEATURES OF 
CHRONIC GVHD 2014  .............................................................................78  
Appendix 5  KARNOFSKY PERFORMANCE STATUS SCORES  ..............................81  
Appendix 6  CONTRACEPTIVE GUIDANCE AND COLLECTION OF PREGNANCY INFORMATION  ................................................................82 
TABLE OF TABLES  
Table  1 Medical Guidelines for Cytokine Release Reactions  .............................................................. 49 
Table  2 Clinical Laboratory Tests  ........................................................................................................ 55 
Table  3 Suspension Rules for Grade 4 -5 RRT, Graft Failure, and Day -100 NRM  .............................. 67 
Table  4 Operating Characteristics of Suspension Rules  ....................................................................... 67 
 
TABLE OF FIGURES  
Figure  1 Study Design Schema  .............................................................................................................. 37 
Figure  2 DLT Schema  ........................................................................................................................... 38 
 
 
 
  
RGI-2001-003   
Page 8 of 84 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020  
1 LIST OF ABBREVIATIONS AND DEFINITIONS  OF TERMS  
Abbreviation  Definition  
aGvHD  Acute Graft versus Host Disease  
ADME  Absorption, Distribution, Metabolism and Excretion  
AE Adverse  Event  
alloHSCT  Allogeneic hematopoietic  Stem  Cell Transplantation  
α-GalCer  α-galactosylceramide  
ALT  Alanine  Aminotransferase  
APC  Antigen  Presenting  Cell 
API Active  Pharmaceutical  Ingredient  
aPTT  Activated  Partial  Thromboplastin  Time  
AST  Aspartate  Aminotransferase  
ATG  Anti-Thymocyte Globulin  
AUC  Area Under the Curve  
BMT  Bone  Marrow  Transplantation  
BP Blood  Pressure  
BUN  Blood U rea Nitroge n 
cGvHD  Chronic Graft versus Host Disease  
Cmax  Maximum  Concentration  
Cmin  Minimum  Concentration  
CBC  Complete  Blood  Count  
CFR Code  of Federal  Regulations  
CIBMTR  Center for International Blood and Marrow Transplant Research  
CRA  Clinical  Research  Associate  
CR Complete  Remission  
CRF  Comprehensive  Report  Form  
CTCAE  Common  Terminology  Criteria  for Adverse  Events  
DC Dendritic  Cell 
DCreg s Regulatory  Dendritic  Cells  
DLT Dose -Limiting  Toxicity  
DST  Donor -Specific  Transfusion  
ET Early Termination  
ECGs  Electrocardiograms  
eCRF  Electronic Case Report Form  
FDA  Food  and Drug  Administration  
FIH First-In-Human  
GCP  Good  Clinical  Practice  
G-CSF Granulocyte  Colony  Stimulating  Factor  
GLP  Good  Laboratory  Practice  
GRFS  Graft vs Host disease free, relapse free survival  
 
 
  
RGI-2001-003   
Page 9 of 84 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020  
Abbreviation  Definition  
GvHD  Graft  versus  Host  Disease  
GvL Graft vs Leukemia  
HBV  Hepatiti s B Virus 
Hct Hematocrit  
HEENT  Head, ears, eyes, nose and t hroat  
HCV  Hepatiti s C Virus 
HED  Human  Equivalent  Dose  
Hgb Hemoglobin  
HIV Human  Immunodeficiency  Virus  
HLA  Human  Leukocyte  Antigen  
HNSTD  Highest  non-severely  toxic  dose 
HR Heart  Rate 
HSCs  Hematopoietic stem cells  
HSCT  Hematopoietic stem cell transp lant 
IB Investigator’s  Brochure  
ICF Informed  Consent  Form  
ICH International  Conference  on Harmonization  
IL Interleukin  
iNKT  Invaria nt Natural  Killer  T (cells)  
INR International  Normalized  Ratio  
IP(s)  Investigational  Product(s)  
IRB Institutional  Review Board  
iTCR  Invariant  T-cell Receptor  
IUD Intra -uterine  Device  
IV Intravenously  
KPS  Karnofsky  Performance  Status  
LDH  Lactate  Dehydrogenase  
MedDRA  Medical  Dictionary  for Regulatory  Activities  
MFD  Maximum  Feasible  Dose  
MHC  Major  Histocompatibility  Complex  
MMF  Mycophenolate  Mofetil  
MTD  Maximum  Tolerated  Dose  
MTX  Methotrexate  
NCI National  Cancer  Institute  
NKT  Natural  killer  T (cell)  
NRM  Nonrelapse  Mortality  
OS Overall Survival  
OTC  Over -the-counter  
PBSCT  Peripheral  Blood  Stem  Cell Transplant  
PBMC  Peripheral  Blood  Mononuclear  Cell 
 
 
  
RGI-2001-003   
Page 10 of 84 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020  
Abbreviation  Definition  
PD Pharmacodynamic  
PE Physical  Examination  
PI Principal  Investigator  
PK Pharmacokinetic  
PT Prothrombin  Time  
QTcF  QTc interval  using  Frederica’s  correction  
RBC  Red Blood  Cell 
RR Respiratory  Rate 
RRT  Regimen -related toxicity  
SAEs  Serious  Adverse  Events  
SGOT  Serum  Glutamic  Oxaloacetic Transaminase  
SGPT  Serum  Glutamic  Pyruvic Transaminase  
SOC  Standard of Care  
SRC  Safety Review Committee  
STD  Severely  toxic  dose 
T1/2 Half-life 
TEAE  Treatment emergent advers e event  
TK Toxicokinetic  
Tmax  Time  to Cmax 
TNF-α Tumor  Necrosis  Factor -alpha  
Tregs  Regulatory  T Cells  
ULN  Upper  Limit  of Normal  
WBC  White  Blood  Cell 
 
 
 
  
RGI-2001-003   
Page 11 of 84 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020  
2 PROTOCOL SYNOPSIS   
Name of Sponsor  REGiMMUNE Corporation (JAPAN)  
35-3 Nihonbashi Hakozaki -cho BRICK GATE 5F, Chuou -ku, 
Tokyo 103-0015 Japan  
Protocol  Title  An Open Label, Non-Randomized Multicenter Phase 2b, 
Study with a Safety Run-in to Evaluate the Safety and Efficacy of RGI-2001 for the Prevention of Acute Graft-Versus- Host Disease Compared to  Conte mporary 
Controls in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) 
Name of Investigational Product  RGI-2001  
Protocol Number  RGI-2001-003  
Phase  Phase 2  
Indication  Prevention of Acute Graft –versus-Host Disease following 
alloHSCT  
Study Centers  This study will be conducted at 8- 12 sites in the United 
States.   
Study Rationale:  Despite efforts to date, the incidence of acute GvHD remains 
high.  Thus, improvements in the prevention of the disease 
constitutes a high unmet medi cal need.  
Studies in both humans and mice have confirmed the pivotal role CD4+Foxp3+ Treg cells play in controlling GvHD 
(
Socié  2009 ). However, the developm ent of Treg cell -based 
therapeutic modalities has been hampered, in part, b y the small 
numbers of these cells. RGI -2001 is a liposomal form 
designed to deliver RGI -7000, which is an immunomodulatory 
compound that may promote the proliferation of Tregs in 
donor bone marrow and the development of tolerance to 
alloantigens and therefore constitutes a novel approach to the prevention of GvHD . 
Objectives  Endpoints  
Primary 
• To assess the potential efficacy of 
RGI-2001 in addition to standard 
of care (SOC) vs SOC for the 
prevention of acute GvHD (aGvHD)
 
• To characterize the safety and tolerability of 6 weekly 
intravenous (IV) infusions of • Efficacy: Grades II -IV aGvHD by Day 100 according to 
the Modified Keystone Criteria  (Przepiorka  1995 ) 
• Safety: Incidence, nature, an d severity of 
treatment-emergent AEs, SAEs, laboratory test values, vital-sign measures, and graft failure 
 
 
 
  
RGI-2001-003   
Page 12 of 84 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020  
RGI-2001 in subjects following 
alloHSCT  
Secondary  
• To assess the potential efficacy of 
RGI-2001 in addition to SOC  vs 
SOC for the prevention of 
chronic GvHD (cGvHD) according to the secon dary 
endpoints listed
 
• To assess the survival of subjects who received RGI -2001 in 
addition to SOC vs SOC 
 
• To evaluate the pharmacodynamics (PD)  effects 
of weekly dosing of RGI -2001
 • Grades II -IV aGvHD by Day 180 according to the  
Modified Keystone Criteria  
• Total and moderate -severe cGvHD at 6 months and 1 year 
according to the 2014 NIH criteria for cGvHD  
• Non-relapse mortality (NRM) rates at Day 100, 6 months 
and 1 year  
• Disease-free survival (DFS) at 6 months and 1  year  
• GvHD-free, relapse free survival (GRF S) at 6  months and 
1 year  
• Overall survival (OS) at 6 months and 1 year  
• Change from baseline in the percentage of CD4+CD25+CD45RA+ CD127-LO T cells (naive Tregs) 
on Days 14, 2 8, 42, 60, 100, 180
 
 
  
 
 
 
  
  
 
 
  
 
 
 
   
 
 
   
  
 
  
 
  
 
  
 
  
  
 
  
   
  
Study Design  This is an open-label, multi-center, single-arm study to 
evaluate six weekly doses of RGI -2001 in combination with 
SOC  treatment for the prevention of aGvHD in subjects 
following alloHSCT. Study subjects will be compared to a 
contem poraneous set of controls from the Center for 
International Bone and Marrow Transplant Research 
(CIBMTR) that is derived using the same eligibility criteria 

 
 
  
RGI-2001-003   
Page 13 of 84 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020  
used for this study. The study will include  a Safety Run -in 
Phase and an Expansion Phase.  
Safety Run-in Phase:  
Subjects will receive open-label RGI -2001 at a dose of 100μg  
/kg, via 30-minute intravenous (IV) infusion on a weekly basis 
for 6 doses in addition to a standard of care (SOC ) GvHD 
prophylactic regimen. The first dose will be administered on 
Day 0 , approximately  30 minutes  and no later than 1 hour  after 
hematopoi etic stem cell transplant (HSCT ) infusion. 
Subsequent doses will be administered  weekly, on Days 7, 14, 
21, 28 and 35.  
Up to two cohorts of 3 subjects each will be enrolled to the Safety Run -in Phase. Initially, 3  subjects will be enrolled, 
treated and assessed for dose -limiting toxicities through Day 
30 (dose limiting toxicity [DLT] window). A safety review 
committee (SRC) will examine all relevant safety data after 
the 3rd subject has reached D ay 30. As a rough guide, a DLT 
rate on the order of 20% or les s would be considered as 
acceptable. Therefore, if 0  subjects are reported to have a DLT  
among the first 3 subjects , consideration will be given to 
enrolling up to 3 additional subjects. However, this decision will not be made solely on the observed occurr ence (or lack 
of) DLTs; rather the SRC will consider the totality of the 
safety data before arriving at a definitive conclusion regarding 
enrollment of additional subjects at the dose of 100μg  /kg. If 
within the first 3 subjects, 1 or more DLT  are observed, then 
consideration will be given to use of an alternative dose and/or dosing schedule, with the ultimate decision being made by the 
SRC. If an alternate dose and/or schedule is used, the same process as described above will be used.  If the addit ional 3 
subjects (beyond the initial 3) are allowed to enroll at the dose 
of 100μg  /kg or a lower dose and/or alternative schedule, 
safety data after the 6th subject has completed all 6 doses, as 
well as initial efficacy, PK and PD data will be evaluated i n 
coming to a recommendation regarding proceeding to the Expansion Phase, with this recommendation made by the SRC.  
Definition of Dose -limiting Toxicities  
The fo llowing DLT criteria apply  to the Sa fety Run -in Phase 
of the study.  A DLT is defined as any treatment -related AE 
that is not attributable to an extraneous cause (e.g., disease 
progression, preparatory regimen or HSCT infusion) and also excludes any signs and symptoms of GvHD.  A DLT is an 
adverse event occurring in the period of 30 days after the first 
dose of RGI -2001 administration, and meeting at least 1 of the 
following NCI  CTC (Version  5.0) criteria: 
• Grade 3+ infusion -related/cytokine release reactions  
 
 
  
RGI-2001-003   
Page 14 of 84 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020  
• Graft failure (as defined in Sectio n 9.4.1 ) 
• Any Grade 4 -5 non-hematological AE  
• Delay in dosing by >  2 weeks due to treatment -related AE 
that is not attributable to an extraneous cause  
Expansion Phase:  
Once a dose/schedule is determined by the SRC to have an 
acceptable safety/PK profile, enrollment will continue in the Expansion Phase and be extended to all sites.   
Accrual is targeted at 50 subjects who receive the dose 
deemed as acceptable from the Safety Run -in Phase (44 in the 
Expansion Phase, 6 from the Safety Run-in Phase at the dose 
used in expansion).   
Subjects will receive open -label RGI -2001 at a dose of 
100μg /kg, via 30 -minute intravenous (IV) infusion on a 
weekly basis for 6 doses (or an alternative dose/schedule as determined in the run-in phase) in addition to a SOC GvHD prophylactic regimen. The first dose will be administered on Day 0 at approximately 30 minutes and no later than 1 hour 
after HSCT infusion. Subse quent doses will be administered 
weekly, on Days 7, 14, 21, 28 and 35.  
Control Group:  
A non-randomized, contemporary control group from the CIBMTR database will be derived for comparison. Control  
subjects will be chosen so as to meet all eligibility requir ements for the clinical trial, have received a transplant in 
the same time window as the study subjects, and have been transplanted in a center that participates in this study. Consent 
will be obtained via the CIBMTR to participate in this study . 
Number o f Subjects  A total of 50 subjects will be enrolled.  It is anticipated that a 
minimum of 250 subjects will be included in the control group.  
Study Duration  Individual subject participation is expected to last up to 1 year following alloHSCT, including a 6 -week treatment period and 
a 42-week follow-up period.  In addition, there is a screening 
period lasting approximately 2 weeks.   
Inclusion Criteria  All subjects (including CIBMTR control group, except where noted) must meet the following criteria: 
1. Ages > 18 and < 65 years of age  
2. Has a hematologic malignancy as defined below and is considered a candidate for alloHSCT: 
a. Acute myelogenous leukemia (AML) in first or subsequent morphologic complete remis sion (CR) 
b. T or B cell acute lymphoblastic leukemia (ALL) in first or subsequent complete morphologic remission  
 
 
  
RGI-2001-003   
Page 15 of 84 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020  
c. Myelodysplastic syndrome (MDS), chronic 
myelomonocytic leukemia (CMML), 
myeloproliferative disorder (MPD) including myeloid metaplasia and myelo fibrosis and are currently with 
< 10% blasts in bone  marrow  
d. CML subjects who have received prior treatment including at least one tyrosine kinase inhibitor and are currently in chronic phase or with a complete hematologic remission but with evidence of cytogenetic or molecular relapse  
3. Must have adequate organ function as defined below  
(RGI-2001treatment group only):  
a. Cardiac function: Left ventricula r ejection 
fraction at rest ≥ 45% 
b. Liver function: total bilirubin < 1.5 x upper limit of normal (ULN); alanine 
aminotransferase (ALT) and aspartate 
aminotrans ferase (AST) < 2.5 x the ULN.  
Patients who have been diagnosed with Gilbert’s Disease or malignant  involvement 
are allowed to exceed the defined bilirubin value of 1.5 x the ULN  
c. Serum creatinine < 2 mg/dL  or estimated 
creatinine clearance > 50mL/min calculated 
using the Cockcroft -Gault equation  
d. Pulmonary: DLCO (corrected for hemoglobin) and/or  FEV1  ≥ 50 % 
4. Considered suitable candidate for a myeloablative allogeneic or unrelated donor transplant based on institutional criteria  
5. Subject must be receiving first allogeneic transplant from a single donor.  Prior autologous transplant is 
acceptable  
6. Transplant Donor: 
a. Matched related donor (8/8): Molecular identity at HLA -A, -B, -C and -DRB1 by 
high-resolution typing  
b. Unrelated donor (≥ 7/8 allelic match): high 
resolution molecular typing at the following loci is required HLA -A, -B, -C and -DRB1 
c. Meets institutional criteria for bone marrow or PBSC donation (see  Section 7.4 ) 
7. Source of the allograft; unmodified bone marrow or  
mobilized peripheral blood stem cell (PBSC) 
transplant, using granulocyte colony stimulating factor 
 
 
  
RGI-2001-003   
Page 16 of 84 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020  
(G-CSF) as the mobilizing agent.  Cord blood is not 
allowed.  
8. KPS ≥  60 
9. Is a candidate for anti -graft-vs -host -disease (GvHD) 
prophylaxis that includes  a calcineurin inhibitor (either 
tacrolimus [FK 506] or cyclosporine A), in 
combination with either methotrexate (MTX), mycophenolate mofetil (MMF).  
10. Ability to understand and willingness to sign a written infor med consent form  
Inclusion criteria pertaining specifically for subjects scheduled to receive RGI-2001:  
11. If female of childbearing potential, must have had a negative serum pregnancy test prior to enrollment and must have agreed to use a double barrier method of contraception for 90 days following the last dose of  
RGI-2001  
12. If male, must be sterile or willing to use an approved method of contraception from the time of informed consent to 90  days after the last dose of RGI -2001  
Exclusion Criteria  Any subjects (i ncluding CIBMTR control group) who meet 
any of the following criteria will be excluded from study entry:  
1. Has had any other prior organ transplantation  
2. Planned procedure to deplete regulatory T -cells from 
donor transplant materials  
3. Planned reduced intensity conditioning  
4. Planned use of any additional or alternative drug(s) for 
GvHD prophylaxis than listed in the inclusion criteria 
(e.g., rapamycin, cyclophosphamide, steroids)  
5. Has had prior treatment with anti -CD3, other T cell 
depleting antibodies, or a nti-thymocyte globulin within 
12 months prior to alloHSCT procedure  
6. Is participating in a trial (ot her than RGI -2001- 003) 
involving an investigational agent/non-standard of care drug  
7. Has progressive underlying malignant disease including post -transplant lymphoproliferative disease  
8. Has evidence of active central nervous system (CNS) 
disease including kn own brain or leptomeningeal 
disease (CT or MRI scan of the brain required only in 
case of clinical suspicion of CNS involvement)  
9. Patients with active bacter ial, viral or fungal infections 
(currently taking medication(s)  and with progression or 
no clinical  improvement)  
 
 
  
RGI-2001-003   
Page 17 of 84 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020  
10. Known history of human immunodeficiency virus 
(HIV)  
11. Active infection with hepatitis C virus (HCV) or 
hepatitis B virus (HBV)  (control group onl y).  
12. Is female and pregnant or lactating  
Exclusion criteria pertaining specifically to  subjects scheduled 
to receive RGI-2001:  
13. Has undergone major surgery within 1  month before 
Day 0. Indwelling catheter placement is allowed  
14. Hepatitis B virus (HBV) or hepatitis C virus (HCV) 
infection with viral load above the limit of 
quantification . Subjects that are on study with HBV or 
HCV infection should have titers checked regularly, as per institutional standard of care  
15. Has had any other condition that, in the opini on of the 
Investigator, renders the subject unsuitable for study participation  
16. Has a documented history of uncontrolled autoimmune disease or on active treatment 
17. Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug.  
18. History of myocardial infarction, unstable angina, or 
acute coronary syndrome within 6 months prior to 
receiving study drug  
19. Has received an investigational agent within 4  half-
lives  or 14 days prior to HSCT, whichever is shorter  
Investigational Product;  Dose; Ro ute of Administration  RGI-2001 for Injection is supplied as a sterile liquid 
suspension filled into depyrogenated USP Type 1, 5- mL glass 
vials with a 2.5 mL fill volume. 
All subjects will receive 6 weekly doses of RGI -2001, 100 
μg/kg via IV administration over 30 minutes. The d osage of 
RGI-2001 will be diluted in 50 m L 0.9% normal saline and the 
first dose will administered intravenously  (IV) at 
approximately 30 minutes and no later than 1 hour after 
completion of the alloHSCT on Day 0.  
 
 
  
RGI-2001-003   
Page 18 of 84 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020  
Conditioning, Proph ylactic and 
Concomitant Therapy Concomitant  medications are any prescription  or over-the-
counter  (OTC) preparations used from 2 days prior to the 
preparatory regimen  before  Day 0 through the end of the 
subject’s study  participation.  
Standard  myeloablative preparatory regimens, (i.e., 
experimental regimens or drugs are not allowed), HSCT, and 
standard supportive care/ prophylactic treatments (including but not limited to colony stimulating factors, transfusions, antibiotics/ anti-virals/  anti-fungals) per institutional 
guidelines for optimal medical care shall be permitted during 
participation in  this study. The dose of steroids that are 
required for reasons unrelated to the underlying malignancy or 
HSCT process or sequelae must not be higher th an physiologic  
doses (the equivalent of 20  mg of prednisone).  No anti -
thymocyte  globul in is allowed in the conditioning regimen.  
GvHD prophylaxis must consist of a calcineurin inhibitor 
(cyclosporine or tacrolimus) in combination with MTX or 
MMF. Dosing, s chedule and monitoring of the GvHD regimen 
should follow institutional guidelines. Please see respective 
prescribing information for safety information. Steroids, sirolimus, post-transplant cyclophosphamide, other GvHD 
prophylactic agents (including invest igational agen ts) or 
manipulation of the graft to reduce GvHD are not allowed.  
Post transplant maintenance therapy that includes an 
investigational agent (ie, not an FDA approved drug for any 
indication) , or any treatments that can be used for GvHD is no t 
allowed. Maintenance therapy  for actionable targeted 
mutations (e.g., FLT3 inhibitors) or with FDA approved 
agents in any indication, should not be initiated prior  to Day 
42 post alloHSCT. 
Treatment of GvHD should follow institutional guidelines and may include steroid  treatment at supra-physiologic doses.  
Statistical Considerations  The primary objective of this study is to assess the potential efficacy of RGI -2001. The primary endpoint for these 
purposes is grades II -IV acute GvHD, and the study subjects 
will be comp ared to a control group of subjects supplied by the 
CIBMTR. Control subjects will be chosen so as to meet all 
eligibility requirements for the clinical trial, have received a transplant in the same time window as the study subjects, and 
have been transplan ted in a center that participates in this 
study.  
 
 
 
 
 
  

 
 
  
RGI-2001-003   
Page 19 of 84 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020  
We consider a one -sided  significance level of .10 to be 
sufficient  evidence of a signal for moving forward.   
 
   
 
   
 
  
    
    
    
    
    
    
    
    
    
Based on these estimates, it is anticipated that a total of 50 
subjects who receive at least one dose of RGI -2001 will be 
enrolled, this including subjects from the run-in stage treated at the dose moved forward to the Expansion Phase. It is anticipated that a minimum of 250 subjects will be included in the control group.  
Demographics and Baseline Characteristics 
Categorical factors will be summarized with proportions, and 
continuous variables will be summarized using means and medians.  
Analysis Population, Handling of Dr opouts, and Missing Data 
All subjects who receive at least one dose of RGI -2001 will be 
used for comparison to the CIBMTR subjects.   
Analysis of Efficacy Data  
The primary endpoint grades II -IV acute GvHD by D ay 100 
according to the Modified Keystone Criteria  will be compared 
between the study group and CIBMTR controls using logistic regression.  The factors that will be considered for adjustment 
in this model include subject age, gender, donor age, type of donor (MRD, 8/8 URD 7/8 URD), source of allograft, diagnosis (AML, ALL, MDS, MPD including CMML), 
preparative regimen, GvHD prophylaxis regimen.  
Secondary endpoints that will be modeled as binary outcomes 
will similarly be compared using logistic regression.  
Secondary endpoints that will be modeled as time -to-event 
outcomes will be compared using Cox regression.  
Potential interactions of RGI -2001 and various factors will be 
examined by including appropriate factors into regression 
models.
 
Given that this is not a randomized study and that the intention 
is on ly to assess outcomes for a potential signal, no 

 
 
  
RGI-2001-003   
Page 20 of 84 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020  
adjustments will be made for multiple comparisons.  As such, a 
Type II error (or a false negative) is prioritized over a Type I 
error (or a false positive).  
Binary exploratory outcomes will be summarized with  
proportions, continuous outcomes with means and medians, 
and time -to-event outcomes with Kaplan -Meier estimates or 
cumulative incidence estimates for endpoints with competing risks.  
 
 
 
  
RGI-2001-003   
Page 21 of 84 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020  
3 SCHEDULE OF ASSESSME NTS  
ASSESSMENTS Screeninga Prior 
to 
HSCT  HSCT/  
RGI-2001  
Infusion  Treatment Period  Follow-up Safety Period  Early 
Termination 
(ET)b Unscheduled 
Visitc 
Day   
-14 to -1 0 0 7 14 21 28 35 42 60 100 180 274 
(9mo)  365 
(12mo)   
 
Visit Window   0 0 (± 
1) (± 
1) (± 1) (± 1)  (± 1) (± 3)  (± 3) (± 5)   (± 5) (± 7) (± 7)    
Informed  consentd X                
Demographics  X                
Inclusion/exclusion criteria  X                
Medical/cancer/ surgical  
historye X                
Vital  signs/ KPSf X X  X X X X X X X X X X X X X 
Weight/ heightg X X  X X X X X   X X  X X  
Physical  examh X X   X  X X  X X X X X X X 
Hematologyi X X  X X X X X X X X X X X X X 
Serum  chemistryj X X  X X X X X X X X X X X X X 
Coagulation testingk X X              X 
Urinalysisl X               X 
Serum  pregnancy  testm X               X 
12-lead ECG  X               X Allogeneic HSCT    X              
RGI-2001 administrationo   X X X X X X         
RGI-2001  PK samples   
 Blood for 
immunophenotyping   
 
  
 
  
GvHD  assessmentp     X X X X X X X X X X X X 
Tumor assessmentsq X          X X  X X X 
Adverse  eventsr X X  X X 
Concomitant  medicationss X X X 
Abbreviations: ET = early termination,  HSCT = hematop oetic stem cell transplant, KPS = karnofsky performance status, ECG = electrocardiogram, PK= pharmacokinetics, GvHD = 
graft vs host disease  
a Screening assessments must be performed within 14 days prior to initiation of any treatments  related to the HSCT including the preparatory regimen unless otherwise 

 
 
  
RGI-2001-003   
Page 22 of 84 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020  
specified.  Informed consent , results of s creening hepatitis , HIV tests, and tumor assessment  (provided that no intervening therapy for their malignancy has been administered) 
may be obtained up to 42 days before initiation of the preparatory regimen.  PFTs and ECHO may be obtained as per institutional standard of care criteria  within 84 days prior 
to the preparatory regimen provided no intervening therapy for their malignancy has been administered. P regnancy t est must be conducted within 7 days before preparatory 
regimen. Results of standard of care  tests/procedures, performed prior to the subject signing the informed consent form (ICF) can be used as part of the screening assessments 
as long as the  tests/proce dures are performed within the appropriate s creening window , unless otherwise specified . Screening assessments do not need to be repeated due to 
minor delays in procurement of donor HSC’s.  
b Subjects who are permanently discontinued from the study, either during the treatment period or follow up period, should complete the Early Termination Visit and, if 
applicable, monitor adverse event through 30 days of last RGI-2001 dose.  
c Unscheduled visits and procedures may be performed as clinically indicated.  
d Written informed consent must be signed by the subject before any protocol required procedures and assessments are performed. Results of s tandard of care tests/procedures, 
performed prior to the subject signing the informed consent form (ICF) can be used as part of the screening assessments as long as the tes ts/procedures are performed within 
the appropriate s creening window  unless otherwise specified. Screening assessments do not need to be repeated due to minor delays in procurement of donor HSC’s.  
e Prior cancer h istory includes: (i) date of diagnosis, (ii) prognostic score if applicable (iii)  all previous therapies ( i.e., chemotherapy, immunotherapy, biologic or targeted 
agents, experimental therapies, radiotherapy, and surgery), (iv) previous therapy details (i.e ., regimen, start and stop dates),  (v) best response for each regimen . 
f Vital  signs,  including  temperature,  blood  pressure  (systolic/diastolic),  heart  rate (HR) , and respiratory  rate (RR)  should be taken in supine or seated position . Vital 
signs should be obtained within 15 minutes prior to RGI-2001 infusion and should be repeated within 30 minutes after the infusion. Additional vital signs measurements 
should be obtained as clinically indicated.  
g Height (without shoes) should be obtained prior to initiation of the preparatory regimen only.  Weight should be taken within one day of dosing  and the dosage of RGI-2001 
should be verified to be the same as the planned dose.  
h A complete physical exam should be performed during screening and should include HEENT, dermatologic, cardiovascular, respiratory, GI (including assessments of liver 
and spleen), musculoskeletal, neurological, and lymphatic systems. Physical examinations at all  other time points  should be  a limited  review of body systems as well as 
symptom-directed physical examinations of an AE or SAE . 
i A complete blood count including red blood cell (RBC) a nd white blood cell (WBC) count with differential, hemoglobin, hematocrit, and platelet count.  
j A comprehensive chemistry panel includes sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, glucose, albumin,  total protein, ca lcium, 
phosphorus, magnesium, total  bilirubin,  direct bilirubin, alkaline  phosphatas e, aspartate aminotransferase (AST ), alanine aminotransferase (ALT ), lactate de hydrogenase 
(LDH) and gamma glutamyl transferase (GGT). 
k Coagulation tests including prothrombin time (PT) or INR, and aPTT should be obtained at baseline and prior to HSCT infusion. Additional test s may be obtained as 
clinically indicated.  
l Urinalysis,  including  protein,  glucose , ketones,  blood,  bilirubin,  urobilinogen, pH, specific  gravity  and nitrates,  with microscopic  examination  of sediment in the event  
of an abnormal  reading  on the dipstick . 
m Serum  pregnancy  test (women  of child- bearing  potential)  – within 7 days  prior  to preparatory regimen. 
n Single ECG to be performed.  If abnormal , including QTc > 450 msec , perform  i n triplicate approximately 30 seconds apart, using the average of the three . 
o RGI-2001 should be administered intravenously over 30 minutes.  On Day 0, the infusion should occur approximately 30 minutes  and no later than 1 hour following the 
completion of HSCT. If cytokine reaction occurs with HSCT, subject should have resolved symptoms prior to the administration of RGI-2001. 
p Assessment for GvHD should be performed during every examination or per institutional guidelines from the time of engraftment to end of study. Documentation of the 
timing, severity is required including any biopsies obtained. Treatment for GvHD and outcome  should be docume nted.  
q Evaluation of status of hematologic malignancy should be conducted as per institutional guidelines but should include a bone marrow aspirate and biopsy with cytogenetics , 
molecular diagnostics  and chimerism as appropriate based on disease histology at baseline, and at time intervals close to Days 100, 180 and 365.  
 
 
  
RGI-2001-003   
Page 23 of 84 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020  
r Adverse event s (AEs)  must be recorded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v. 5.0) where  possible. The 
reporting period for non-serious AEs starts after the first administration of study drug on Day 0.  The reporting period for serious AE s starts after the informed consent form 
(ICF) has been signed. Adverse event monitoring should be continued for at least 30  days following the last dose  of study drug.  Infections should be recorded throughout the 
study. See Section  10 for further details.  
s Review of all medications, including over-the- counter (OTC) preparations and herbal products. Concomit ant medications  used from 2 days prior to the preparatory regimen 
before Day 0 through the end of the subject’s study participation, should be recorded. Maintenance therapy should be documented as a concomitant medication.
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 24 of 84 
4 INTRODUCTION  
4.1 Background  
4.1.1 Graft Versus H ost Disea se 
Allogeneic hematopoietic stem cell transplantation ( alloHSCT) is an important therapeutic 
option, and, in some indications , the only potentially curative therapy, for the treatment of a 
variety of hematologic malignancies, including acute myelogenous leukemia (AML), acute 
lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML) and myelodysplastic syndrome (MDS). In the U.S. approximately 8,500 subject s underwent allogeneic HSCT for a 
variety of indications in 2016. 
The success of myeloablative alloHSCT derives both from the ability to treat subject s with 
intensive chemo radiotherapy  and from potent graft- versus -leukemia (GVL) effects mediated by 
donor immunity. Donor T cells in the infused stem cell graft are used to attack malignant cells, 
but m ay also strike  normal host tissues and  organs, resulting in graft versus host disease ( GvHD).  
Despite the use of immunosuppressive agents, GvHD , acute or chronic, is one of the leading 
causes of morbidity and mortality from alloHSCT.  
Five phases of the development of acute GvHD have been described  (Socié  2019). The first 
phase, priming of the immune response, is initiated by the underlying disease and the 
conditioning regimen used to prepare for transplantation. Damage to host tiss ues results in the 
secretion of pro -inflammatory cytokines that can increase the ex pression of adhesion molecules, 
co-stimulatory molecules, major histocompatibility complex ( MHC) antigens and chemokines - 
all of which activate host antigen presenting cell s (APCs). The second phase, T- cell activation 
and co-stimulation occur when donor T cells proliferate and differentiate in response to host 
APCs. The incidence of acute GvHD is directly related to the degree of mismatch in human 
leukocyte antigen (HLA) det erminants such as MHC class II and I and minor histocompatibility 
antigens (MiHA). Additional donor/host differences, such as polymorphisms in proteins 
connected with innate immunity (NOD2), in the Toll-like receptor family, and in cytokine genes, 
are also  believed to contribute to acute GvHD risk. The third and fourth phases of acute GvHD 
include alloreactive T -cell expansion and differentiation followed by the migration of activated 
T-cells to GvHD  target tissues such as the gut, liver, skin, and lung and the recruitment of other 
effector leukocytes. In the last phase of acute GvHD deve lopment, effector T -cells initiate the 
destruction of target tissues via exposure to the cell surface and the release of soluble immune 
effectors. The resultant tissue damag e leads to an increase in inflammatory signals and 
propagation of the cytokine stor m. 
Classic acute GvHD generally develops within the first 100 days after myeloablative HSCT and typically affects the skin, gastrointestinal (GI) tract, and liver. In the se tting of prophylaxis with 
immunosuppressants, Grade II- IV acute GvHD occurs in 25-60% of matched related transplant 
recipients and in 45 -70% of matched unrelated recipients ( Ho 2001). Although less common 
with myeloablative transplants, late onset acute GvHD  may occur after 100 days post HSCT. The 
incidence of acute GvHD increases with increasing HLA mismatch between donor and recipient , 
unrelated donor transplant, female donor to male recipient and use of a total body irradiation (TBI ) containing preparatory regimen. The development of Grade III /IV acute GvHD is 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 25 of 84 
associated with a decrease in survival in subject s undergoing allogeneic transplantation. Steroids, 
primarily prednisone and methylprednisolone, constitute the first line of treatment for 
Grade  III-IV acute GvHD. Complete responses can be expected in 25-35% of subject s, with an 
additional 15% achieving a partial response. Failure to respond to steroid therapy portends a poor 
prognosis. Second line treatment for acute GvHD include other immunosuppressive agents, such 
as tacrolimus, and anti -thymocyte globulin (ATG), as well as agents targeting TNF- α and the 
IL-2 receptor ( Paczesny 2 010). These therapeutic approaches are complicated by broad 
immunosuppression that results in enhanced susceptibility to infection and the risk of recurrence of the underlying malignancy. 
4.1.2 CD4+Foxp3+ R egulatory T -cells 
A number of approaches, both pharmaceutical and cellular, in the prophylaxis of acute GvHD are 
being studied. The mainstay of prophylaxis therapy is a combination of a calc ineurin inhibitor 
(cyclosporine and tacrolimus) plus either a short course of methotrexate or mycophenolate mofetil. More recently, sirolimus, which has been successful in the prevention of organ 
transplantation, has been utilized for acute GvHD. To  date, no single combination has proved 
superior in the prevention of acute GvHD, and the incidence of acute GvHD remains high. Cellular approaches have included T -cell depletion, either ex vivo or in vivo and the positive 
selection of stem c ells (to facilitate the exclusion of T- cells). While these efforts have had an 
impact on the incidence of acute GvHD, when used aggressively, these techniques have been associated with higher disease relapse rates ( Paczesny 2010).
  
More recently, ef forts have been made to understand the function of regulatory T cells in 
transplantation. CD4+Foxp3+ Treg cells are considered a key player in maintaining peripheral tolerance ( Wing 2001, Sagoo 2008, Paczesny 2010 ). Animal studies have demonstrated that 
these cells prevent or ameliorate various T -cell mediated diseases, including autoimmune disease 
and GvHD, by restoring immune tolerance to self -antigens as well as alloantigen s (Wolff 2009 ). 
Studies in both humans and mice have confirmed the pivotal role Treg cells play in controlling GvHD ( Socié 2019). Ho wever, the development of Treg cell- based therapeutic modalities has 
been hampered, in part, by the small numbers of these cells. RGI -2001 can expand these Treg 
cells in vivo and thus constitutes a novel approach to the treatment of GvHD .  
The relationship between Treg cells and acute GvHD  in clinical allogeneic bone marrow 
transplantation (BMT) recipients has been assessed clinically. A prospective analysis of peripheral blood Treg cells as determined by the frequency of CD4+CD25hiFoxp3+ lymphocytes was conducted in 215 BMT subj ects (Magneau 2010). Autologous BMT subjects 
(N = 90) and allogeneic BMT subjects without GvHD (N = 65) had similar cell frequencies, whereas allogeneic subject s with GvHD (N = 60) had Treg cell frequencies that were 40% less 
than those without GvHD. Treg cell frequencies decreased li nearly with increasing grades of 
GvHD at onset, and correlated with the eventual maximum grade of GvHD (P < 0.001). In addition, the number of Treg cells at onset of GvHD predicted the response to GvHD treatment (P < 0.003). Subject s with Treg cell frequen cies less than the median had higher non-relapse 
mortality than subject s with Treg cells greater than the median, but experienced equivalent 
relapse mortality, resulting in an inferior survival at 2 years (38% v ersus 63%, P  < 0.03). Treg 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 26 of 84 
cell frequency may  therefore have important prognostic value as a biomarker of acute GvHD 
(Magneau 2010).  
4.2 Investigational Product  
RGI-2001 is a liposomal formulation of the compound known as RGI -7000. RGI -7000 is a 
synthetic glycolipid composed of a galactose and a ceramide moiety linked in an 
α-configuration, a derivative of α -galactosylceramide (α- GalCer), a glycolipid originally 
extracted from a marine sponge  (Natori 1 993). It serves as a ligand for the CD1d molecule, 
expressed on  APCs ( Kawano 1997, Brossay 1998). The CD1d molecule is a non-polymorphic, 
MHC class I –like antigen -presenting molecule with an antigen -binding groove adapted for the 
presentation of lipid antigens ( Moody 2005, Brigl 2004).  
 
 
 
Refer to the current  edition of the Investigator’s Brochure  (IB)  for additional information  related 
to the physical, chemical and pharmaceutical properties and formulation  of RGI -2001. 
4.3 Study Rationale 
Despite efforts to date, the incidence of acute GvHD remains high. Thus, impr ovements in the 
prevention of the disease  const itutes a high unmet medical need.  
Studies in both humans and mice have confirmed the pivotal role CD4+Foxp3+ Treg cells play in controlling GvHD ( Socié  2009). However, the development of Treg cell-based therapeutic 
modalities has been hampered, in part, by the small numbers of these cells. RGI -2001 is a 
liposomal form de signed to deliver RGI-7000, which is an immunomodulatory compound that 
may promote the proliferation of Tregs in donor bone marrow and the development of tolerance 
to alloantigens and therefore constitutes a novel approach to the prevention of GvHD. 
Precli nical studies suggest that the effects of RGI-2001 treatment are immunologically selective, 
affecting responses against speci fic antigens without causing generalized immunosuppression or 
the depletion of B- or T-cell function or numbers, and that RGI-2001 does not compromise 
beneficial GvL. In vitro and in vivo studies using model antigens have determined the mechanism for RGI-2001’s immunomodulatory activity. These studies have shown that 
RGI-2001 activates a tolerogenic cellular pathway, which ultimately leads to the activation of 
cellular cascades including regulatory dendritic cells  (DCreg) and Tregs. These antigen- specific 
Tregs have been shown to down regulate the immune response directed toward specific antigens without causing generalized immunosuppression. In vivo experiments have also shown that 
primary antibody (humoral) responses were suppressed when mice were exposed to a prototypic preparation of liposomal RGI-7000 at or around the time an antigen was introduced ( Ishii 2008). 
Furthermore, in a murine model of acute GvHD, treatment with RGI-2001 resulted in a statistically significant p rolongation of survival in animals treated at doses ranging from 0.1 to 
100 µ g/kg. In the treated animals, significantly higher levels of host alloantigen -specific Tregs 

 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 27 of 84 
were observed after hematopoietic cell transplantation when compared with untreated animals. 
Immune responses against host alloantigens were suppressed in these treated mice, but 
responsiveness to third -party alloantigens remained intact. Additionally, in a mouse model of 
graft -versus- leukemia (GvL), treatment with RGI-2001 at the time of a llogeneic bone marrow 
transplant was clearly shown to suppress GvHD without abrogating GvL effects  
(Duramad  2011). 
4.4 Summary of Nonclinical Data  
RGI-2001 is anticipated to elicit antigen-specific immune tolerance. In vitro and in vivo studies 
have demonstrated the biological activity of RGI-2001 as follows: 
• RGI-2001 has been shown in vitro to be effectively taken up by B cells.  
• In peripheral blood mononuclear cell (PBMC) and whole blood studies to assess 
cytokine induction, RGI -2001 at clinically relevant concentrations, did not induce 
significant levels of pro -inflammatory cytokines in either human PBMCs or whole 
blood, demonstrating the low potential for inducing cytokines that may play an inciting role in GvHD (e.g., IL-12, IFN- γ or TNF -α).  
• In an acute GvHD model, RGI -2001 induced host-specific tolerance by promoting 
significant and dose dependent expansion of donor-derived CD4+Foxp3+ Tregs following allogeneic bone marrow and whole spleen cell (WSC) transplantation. The 
expansion of Tregs was also associated with a significant survival benefit and improvement in clinical signs of GvHD without compromise of GvL effe cts. 
• Concurrent treatment of normal mice with RGI-2001 and allogeneic donor spleen 
cells resulted in tolerance specific to the donor alloantigens through expansion of 
DCreg and Treg cells in a donor- specific transfusion (DST) mouse model 
(REGiMMUNE  interna l report.  
• In the GvHD efficacy studies a highly significant survival benefit was seen in  mice 
treated with single injections of RGI- 2001 at doses as low as 0.1 μg/kg. A dose -
dependent donor derived CD4+Foxp 3+ Treg expansion was observed at doses 
ranging fr om 0.01 to 100 μg/kg. The survival benefit in these models reached 
significance at appro ximately 0.1 ug/kg. Thus, the minimum pharmacologically 
active dose (PAD) in the mouse GvHD model was defined as 0.1 μg/kg based on both 
survival and Treg expansion. 
In good laboratory practice ( GLP ) toxicology studies in the mouse  (doses of 0.25, 3.5, or 
50 mg/kg every 3 days) and monkey (doses of 0.1, 1.5, or 20 mg/kg every 3 days), doses up to 50 mg/kg and 20 mg/kg of RGI -2001 respectively, the maximum feasible doses (MFD) , did not 
result in significant toxicity or dose limiting adverse effects. RGI-2001 was administered 
intravenously every 3 days to mice and monkeys for a period of up to 2 weeks, for a total of 
5 doses . These repeat dose studies included complete clin ical, as well as morphological 
evaluations in addition to immunophenotypic analyses. Although the severely toxic dose – 10 
(STD -10) or the highest non- severely  toxic dose ( HNSTD) was not reached in the mouse or 
monkey repeat dose toxicology studies, the hi ghest dose was considered the no observed adverse 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 28 of 84 
effect level (NOAEL) . The human equivalent dose (HED) of the NOAEL in the mouse 
(50 mg/kg) is 4400 µg/kg and the HED of the NOAEL in the monkey (20 mg/kg) is 6450 µg/kg. 
These HEDs are 44 - to 65 -fold higher than the dose planned in study RGI-2001-003 (100 µg/kg), 
To supplement the general toxicology studies a single primate GLP safety pharmacology study 
encompassing CNS, cardiovascular, and respiratory evaluations was conducted. This study 
assessed intraveno us doses of up to 20 mg/kg (the same doses evaluated in the definitive 
toxicology study in the monkey), employing telemetry to monitor cardiovascular responses. 
Cardiovascular parameters were also monitored in the repeat -dose GLP toxicology study in 
monkeys.  
RGI-2001 administration did not result in any mortality and was without effect on functional 
observational battery (FOB) parameters.  In addition, there were no significant effects on; body 
weight, body temperature, PR interval, QRS duration, QTc interval, QT vs. RR or QTc vs. RR interval plots, electrocardiographic morphology evaluations, respiratory rate, minute volume, or tidal volume. 
Toxicokinetic (TK)  evaluations were performed for each of the pivotal toxicology studies in 
mice and monkeys and demonstrated adequate exposure throughout the course of the studies. 
Mass balance (i.e., excretion into urine and feces) studies were conducted in mice and monkeys 
using radiolabeled RGI-2001. In addition, a tissue distribution and expired air study was 
conduct ed in mice.   
In both mice and monkeys, radioactivity following [
14C]RGI -2001 administration was associated 
more with plasma than blood cells over the first several hours post- treatment, but the terminal 
half- life (T ½)  in cells (> 250 hours) was much longer than in plasma (~ 50 hours).  
After administration of [ 14C]RGI -2001 to mice, different tissues reached peak radioactivity levels 
at different times with widespread distribution of radioactivity to tissues still observed at 168 hours post- dose. Tissues wi th notably high radioactivity levels were the spleen, liver, bone 
marrow, lung, and adrenal gland. These distribution data were consistent with established 
clearance mechanisms for liposomes through the reticuloendothelial system (Ishida 2002).
 Some 
of the tissues with the highest radioactivity were those associated with histopathologic alterations 
in the mouse toxicology study. Tissues with notably low radioactivity were the central nervous 
system (CNS), ocular tissues, bone, skel etal muscle and reproductive tissues.  
Excretion studies in both mice and monkeys demonstrated that very little RGI-2001 was 
eliminated in the urine and feces. In monkeys, 2.88% was eliminated in the urine and 0.91% in 
the feces. In mice < 6% was eliminated in urine and feces combined. In bile duct-cannulated 
mice, it was shown that only 0.11% of the injected radioactivity was collected in bile over 
24 hours. Collection of expired air yielded 64.68% of the injected dose as CO 2, indicating the 
major route of elimination was conversion of [ 14C]RGI -2001 to CO 2. 
The s pecies used in the absorption, distribution, metabolism and excretion 
(ADME)/toxicokinetic evaluations of RGI- 2001 were the same species employed in the 
pharmacological evaluations (mouse, cynomolgus monkey) and definitive toxicology studies. To date, no m etabolism studies of RGI-2001 have been conducted. The expected consequence of the 
metabolism of liposomal products such as RGI-2001 is degradation to the individual 
phospholipid components and/or t riglycerides  (Seltzer 1984).  
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 29 of 84 
An in vitro study was performed with appropriate positive and negative controls to determine if 
RGI-7000, the active pharmaceutical ingredient ( API) of RGI -2001, inher ited human cytochrome 
P450 enzymes. This study was conducted with RGI-7000 rather than RGI-2001 because it was considered a more sensitive means with which to assess inhibitory potential. Under experimental conditions, there was little or no evidence that RGI-7000 inhibited CYP1A2, CYP2B6, CYP2C8, 
CYP2C9, CYP2C19, CYP2D6 or CYP3A4/5 in either a direct, time -dependent without 
metabolism or metabolism-dependent manner.  
The protein binding capacity of RGI-2001 and RGI-7000 was assessed in mouse, monkey, and 
human plasma. 
 
 
 
Refer to the current edition of the RGI-2001 IB for additional information related  to RGI -2001 
clinical experience.  
4.5 Summary of Clinical Data  
The first in human (FIH) study of RGI -2001 was a Phase 1/2a multicenter, open- label, dose 
escalation study whose primary objective was to evaluate the safety, tolerability, and 
pharmacokinetic prof ile of a single dose of RGI -2001 in subject s undergoing allo HSCT , with 
radiation or non- radiation containing myeloablative or reduced intensity  preparative treatment s 
based on institutional practices. GvHD prophylaxis consisted of a calcineurin inhibitor and one of the following (based on institutional practices): methotrexate, mycophenolate mofetil, or sirolimus. The study was divided into 2 parts: Part 1 was the dose- escalation phase and Part 2 
was the dose -expansion Phase . Eligible subjects were enrolled  at 7 centers. A total of  
68 subjects, 57 RGI -2001 treated  subjects as well as 11 control subject s participated in the study. 
In Part 1 of the study, a total of 28 subjects with a variety of hematologic diseases received a 
single dose of RGI-2001, administered approximately 30 minutes and no later than 1 hour after 
alloH SCT with an unrelated peripheral blood or bone marrow donor graft. The dose ranged from 
0.001 ug/kg to 100 ug/kg. Based on the results of the P art 1 study, 2 doses, w ere selected to 
further study in the Part 2 for the dose-expansion. The maximal administered dose that had no significant toxicity and had some signal of effect was 100 μg/kg. A dose 2 logs lower (1 μg/kg) 
was chosen to evaluate the potential dose response between the 1 μg/kg and 100 μg/kg doses in 
an effort to see a dose resp onse in Part 2 of the study.  
In the Part 2 dose-expansion phase of the study, 29 subjects receiving matched related or 
unrelated donor grafts were randomized to receive a single infusion of either 1.0 ug/kg or 
100 ug/kg R GI-2001 administered approximately 30 minutes and no later than 1 hour after 
alloH SCT. Fourteen subjects received a dose o f 1.0 ug/kg and 15 subjects received a dose of 
100 ug/kg of RGI -2001. An additional 11 subjects were enrolled as control subjects.  A subset o f 
subjects comprised of 4  subjects from each cohort , (8 of  29, 28%) responded to RGI-2001 by 
inducing a markedly in creased number of cells with a Treg phenotype. The Treg  had a high 

 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 30 of 84 
Ki-67 index and were almost exclusively Helios+ and Foxp3+, indicating that their accumulation 
was due to expansion of natural Tregs. Notably, the incidence of grade 2 to 4 GvHD in the 8 
subject s who responded to RGI -2001 was 12.5%, compared with 52.4% in the 21 subject s who 
did not respond. No grade 3 or 4 GvHD was observed in the responder group, compared with a 
9.5% incidence among nonresponders  (Chen 2017).  
The e xpansion of Treg cells was observed through Day 22 relative to the control group. Treg 
increases appeared to be  inversely related to the severity of GvHD . There was no impact on 
myeloid or platelet engraftment noted.  
In general, the mean Cmax was increased  as the dose of RGI -2001 increased. For most cohorts 
and for the subjects who received either the 1 μg/kg or 100 μg/kg dose of RGI -2001 in Part 2, the 
median  times to Tmax were between 0.5 and 0.7 hours. 
RGI-2001 was well tolerated and without infusion reactions or cytoki ne release syndrome up to a 
dose level of 100 μg/kg administered as a s ingle intravenous infusion in subjects who under went 
allogeneic transplantation.  There were no notable adverse effects across a variety of conditioning 
regimens an d regimens for GvHD prophylaxis.  
This study served as the proof of concept for further explo ring the potential of RGI-2001 for 
repeat administration to reduce or prevent GvHD during the critical phase post-transplantation. 
Refer to the current edition of the RGI -2001 IB for additional information related to RGI -2001 
clinical experience.  
4.6 Risks/Ben efits 
Despite utilization of doublet prophylactic regimens, GvHD remains  the largest factor 
influencing outcome from HSCT. Transplant related mortality rates incre ase with increasing 
severity of acute G vHD. Thus, additional treatments are needed. RGI -2001 has demonstrated the 
potential for Treg expansion and a subsequent decrease in acute G vHD without significant 
toxicity.  
Clinical experience consists of the Phase 1  study which is described in Section 4.5. The MTD 
was not reached in doses ranging from 0.001 µg/kg to 100 µg/kg. There were no notable adverse effects across a variety of conditioning and GvHD prophylaxis 
regimens. The expansion of regulatory T- cells was observed up through Day 22 as compared to 
the control group. Correlation of r egulatory T c ell increase appeared to be in inverse relation 
with severity of GvHD.  
All subjects achieved myeloid engraftment within 30 days following RGI-2001 administration. 
Two subjects (both in cohort 2 [0.01 µg/kg]) did not  achieve platelet engraftment within the time 
period; platelet engraftment for 2 other subjects  was unknown (1 in the 1.0  µg/kg group and 1 in 
the 100 µg/kg  group) . Three subjects in the control group did not have platelet engraftment 
within 30 days follow ing RGI -2001 administration. 
All of the subjects who received RGI -2001 reported at least 1 treatment- emergent adverse event  
(TEAE)  during the protocol- specified re porting period. There were no TEAEs that led to 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 31 of 84 
discontinuation from the study. No cytokine r eactions or infusion -related reactions were 
observed.  
The most frequently reported adverse events  for all cohorts  (those occurring in > 15% of the 
subjects who re ceived RGI -2001) were diarrhea (63.2%); nausea (61.4%); mucosal inflammation 
(56.1%); fatigue (54.4%); febrile neutropenia (43.9%); vomiting (36.8%); hypertension (33.3%); 
rash and headache (31.6% each); peripheral edema (29.8%); constipation (28.1%); musc ular 
weakness (24.6%); dyspnea, abdominal pain, and increased AST (22.8% each); pyrexia and 
stomatitis (21.1% each); tachycardia and chills (19.3% each); decreased appetite and myalgia 
(17.5% each); and increased blood creatinine and hypomagnesemia (15.8% each).  
The TEAEs considered related to RGI -2001 (those occurring in ≥  4 subjects in the  all RGI -2001 
group) were nausea (10/57 subjects, 17.5%); diarrhea and increased AST (9/57 subjects each, 
15.8% each); febrile neutropenia (8/57 subjects, 14.0%); vomiting, increased ALT, and increased 
alkaline phosphatase (6/57 subjects each, 10.5% each); chills, fatigue, increased bilirubin, increased creatinine, and headache (5/57  subjects each, 8.8% each); and peripheral edema, 
myalgia, dizziness, and rash (4/57 subj ects each, 7 .0% each)  
Grade 3 TEAEs (those occurring in ≥  4 subjects in the a ll RGI-2001 group) were febrile 
neutr openia (24/57 subjects, 42.1%), mucosal inflammation (13/57  subjects, 22.8%), 
hypertension (10/57 subjects 17.5%), diarrhea (7/57 subjects, 12.3%), stomatitis (6/57  subjects, 
10.5%), and nausea (5/57 subjects, 8.8%). Grade 4  TEAE included  sepsis in 1  subject (100 µg/kg 
group), and septic shock and respiratory failure in another subject (100 µg/kg group). 
The following SAEs occurred in ≥  2 subjec ts in the a ll RGI -2001 group: pyrexia, GvHD, and 
venoocclusive disease (3  subjects each); and diarrhea, sepsis, and staphylococcal bacteremia 
(2 subjects each).  
Based on the nonclinical safety data available for RGI -2001, potential side effects associated 
with the administration of RGI -2001 include:
 
•  Extramedullary hematopoiesis and splenomegaly ; observed in a nimals receiving 
multiple high dose injections of RGI-2001. Although extramedullary hematopoiesis is 
rare in humans, subjects will be monitored closely with complete blood  counts (CBC) 
and physical exam for eval uation of splenomegaly. 
• Microgranulomas; observed in the liver of animals receiving multiple high dose 
injections of RGI-2001. Subjects will have liver function tests monitored frequently throughout the course of the study. 
• Changes in RBCs, reticulocytes, WBC, leukocytes and various T- and B- cell 
lymphocyte subsets. Decline in RBCs may result in anemia, while decline in 
lymphocyte subsets may increase susceptibility to some types of infection. Subjects 
will have frequ ent CBCs to monitor for significant changes in red and white blood 
cell populations. 
• A mild decline in triglycerides ; observed in preclinical safety studies. It is anticipated 
that such a decline will have little impact on safety in subjects.   
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 32 of 84 
The pharmacologic actions of RGI-2001, manifested by a decrease in iNKT cells, could result in 
an impaired immune response to various pathogens and in absolute changes in T- cell or B -cell 
lymphocyte counts. Additionally, the ability of RGI-2001 to induce a tolerogenic state could result in undesirable tolerance to antigens to which subjects are exposed in the interval surrounding the administration of RGI-2001. 
Literature reports have linked the activation of iNKT cells with the progression of atherosclerosis 
in murine models of atherogenesis ( Tupin 2004).  The role of iNKT cells in the development of 
atherosclerotic lesions in humans is unknown; however, inflammation and the innate immune 
response are believed to contribute to the progression of atherosclerosis. Pharmacologically 
active doses of RGI -2001 are expected to activate iNKT cells and theoretically could, as a result, 
aggravate underlying atherosclerotic disease. Only subjects with adequate cardiovascular 
function without ischemia or myocardial infarction in the previous six m onths will be enrolled in 
the clinical study. 
4.7 Dose Regimen and Treatmen t Period Rationale 
The dose and dose schedule for the Phase 2 study is 100 µg/kg, weekly for a duration of 5 weeks 
(6 doses). This dose was selec ted based on nonclinical pharmacology and toxicology information 
and the safety and exploratory efficacy results of the P hase 1/2a FIH study. 
In murine models of GvHD, doses as low as 2 µg/mouse (approximately 100 µg/kg) prolonged the survival of mice . Additional studies  showed pr olongation of survival in these murine models 
was noted over a dose range of 0.1 to 10 µg/kg. As there was no sign of decreasing efficacy with 
dose, these mouse models suggested a dose of 100 µg/kg was toward the top of a wide range of 
effective doses.  
In 2-week GLP toxicity studies of RGI-2001 in the mouse and monkey, the NOAEL was the 
highest dose tested in each species, 50 and 20 mg/kg, respectively. The HED of these doses are 
44-fold and 65-fold higher than the planned dose of 100 µg/kg in study RGI-2001-003. Exposure 
of mice and monkeys at the NOAEL, based AUC0- t was very large, 2,155,000 ng*h/mL and 
12,950,000 ng*h/mL, respectively. These exposures are over 10,000-fold higher than the human AUC0 -t associated with a dose of 100 µg/kg (133 ng*h/mL, n = 15, study RGI -2001-002, 
Part 2). 
Longer term toxicity of the active agent (RGI-7000) given by daily IV injection has been evaluated in GLP studies in rats (50, 100, 200, and 400 µg/kg/day for 26 weeks) and monkeys 
(30, 60, 200, and 600 µg/kg/day for 15 weeks), with a toxicity pattern similar to that of RGI-2001 suggesting there is no change in the toxicity of the active agent of RGI-2001 with 
longer duration of treatment. 
Further support for the selection of 100 µg/kg comes from the clinical safety seen in study 
RGI-2001-002, in which RGI- 2001 was safe and well tolerated up to 100 μg/kg administered as 
a single intravenous infusion for subjects who received allogeneic transplantation. There were no 
notable adverse effects across a var iety of conditioning regimens and GvHD prophylaxis. 
Possible efficacy was observed in subjects during Part 1  (dose escalation) of the study but the 
differences between doses were not clear because of the small sample sizes.  In Part 2 (dose 
expansion), both doses at 1.0 µg/kg and 100 µg/kg dose level showed some signal of effect and 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 33 of 84 
there was no increase toxicity at the highest dose evaluated. There were no trends in toxicity with 
dose escalation  across all the cohorts. Therefore, RGI 2001 at 100 ug/kg was s elected to further 
evalu ated for repeat dosing for the clinical development program.   
Potential signals of efficacy from a single dose of RGI-2001 in study RGI-2001- 002 support 
further testing of repeated (weekly) doses of RGI-2001 in this study. The weekl y interval was 
selected to extend the exposure seen in the single dose clinical trial RGI -2001-002, while 
minimizing subject inconvenience with clinic visits.  
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 34 of 84 
5 STUDY OBJECTIVES AND END POINTS   
Objectives  Endpoints  
Primary  
• To assess the potential efficacy of RGI -
2001 in addition to standard of care 
(SOC) vs SOC for the prevention of aGvHD  
• To characterize the safety and tolerability of 6-weekly  IV infusions of 
RGI-2001 in subject s following 
alloHSCT  •
 Efficacy: Grades II -IV aGvHD  by Day 100 accord ing 
to the M odified Keystone Criteria ( Przepiorka  1995 )  
• Safety: Incidence, nature, and severity of 
treatment-emergent AEs, SAEs, laboratory test values, 
vital sign measures, and graft failure   
Secondary   
• To assess the potential efficac y of RGI -
2001 in addition to SOC vs SOC for the prevention of chronic GvHD (c GvHD ) 
according to the secondary endpoints listed 
• To assess the survival of subjects who received RGI -2001 in addition to SOC 
vs SOC  
• To evaluate the pharmacodynamics effects of w eekly dosing of RGI -2001  • Grades II -IV aGvHD  by Day 180 according to the 
Modified Keystone Criteria  
• Total and moderate-severe cGvHD at 6 months and 1 year according to 2014 NIH criteria  
• Non-relapse mortality  (NRM) rates at Day 100, 
6 months and 1 year   
• Disease-free survival (DFS) at 6 months and 1 year  
• GvHD-free, relapse free survival (GRFS)
a at 6 months 
and 1 year  
• Overall survival (OS)  at 6 months and 1 year  
• Change from  baseline in the percentage of 
CD4+CD25+CD45RA+ CD127-LO T cells (naive 
Tregs) on Da ys 14, 28, 42, 60, 100, 180  
  
•  
 
  
 
  
 
 
   
 
   
  
  
 
  
 
  
 
  

 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 35 of 84 
Objectives  Endpoints  
•  
 
  
  
  
a A GRFS  event includes grade III -IV acute GVHD, chronic GvHD requiring systemic immunosuppressive 
treatment, disease relapse or progression, or death by any cause.  
 

 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 36 of 84 
6 STUDY DESIGN 
This is an open -label,  multi -center, single- arm study to evaluate six weekly doses of RGI-2001 in 
combination with SOC treatment for the prevention of a GvHD  in subjects following allo HSCT . 
The study will include a Safety R un-in Phase of up to 6 subject s to assess the safety and 
tolerability of 6 weekly doses of RGI -2001. If the s afety profile in this run -in is deemed 
acceptable (see Section 6.1), an Expansion Phase in which the potential efficacy of 6 weekly 
doses of RGI-2001 in addition to SOC for GvHD  prophylaxis will be assessed . Comparison will 
be made to  a contemporaneous control group of subjects from the CIBMTR database in which 
SOC GvHD prophylaxis was administered  (details in Section 11).   
All s ubjects will be assessed for suitability of allo HSCT  based on institutional practice, using 
either a matched -related donor (MRD) or unrelated donor ( URD ), and will be enrolled after 
meeting inclusion/exclusion criteria for this study. Preparatory regimens will be based on 
institutional practice for the disease subtype. Either bone marrow or peripheral stem cell grafts 
mobilized with G -CSF will be used. GvHD prophylaxis must consist of a calcineurin inhibitor 
(tacrolimus or cyclosporine) and a second agent (methotrexate or mycophenolate mofeti l. 
All subjects will be assessed for GvHD as per institutional practices but at minimum Day +100, +180 and 1- year post alloHSCT. Assessment  of cGvHD will likewise occur at regular intervals 
as per institutional guidelines . Similar to the methodology employed by CIBMTR for the control 
subjects, cumulative data will be captured at regular intervals as outlined in the Schedule of Assessments (So A). 
• Safety will be assess ed with periodic vital signs, physical exams, laboratory 
assessments and by reporting of AEs. 
• Disease status will be assessed via regular laboratory and bone marrow assessments.  
The study design is presented in Figure  1. 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 37 of 84 
Figure  1 Study Design Sche ma 
 
6.1 Safety Run-in Phase  
A Safety R un-in Phase will be used to assess the safety profile and tolerability of repeat doses of 
RGI-2001 prior to the Expansion Phase. This portion of the study will be conducted at a limited 
number of sites.  
Subjects will re ceive open- label RGI -2001 at a dose of 100μg  /kg, via 30-minute intravenous 
(IV) infusion on a weekly basis for 6 doses in addition to a SOC GvHD prophylactic regimen. 
The first dose will be administered on Day 0 at approximately 30 minutes and no later than 1 
hour after HSCT infusion  (see S ection  8.6 on Dose Administration). Subsequent doses will be 
administered weekly, on Days 7, 14, 21, 28 and 35. 
Up to two cohorts of 3 subject s each will be e nrolled to the Safety R un-in Phase. Initially, 
3 subjects will be enrolled, treated and assessed for dose- limiting toxicities (as defined below in 
Section  6.1.1) through Day 30 (DLT window) . A safety review committee (SRC) will examine 
all relevant safety data after the 3rd  subject has reached Day 30 . As a rough guide, a DLT r ate on 
the order of 20% or less would be considered as acceptable.  Therefore, i f 0 subjects are  reported 
Screening Phase
AML/ALL/MDS/CMLL/MPD/CML
Enrollment Phase
Safety Run -in: n=6
Expansion: n=44
Conditioning Regimen: Myeloablative Conditioning
AlloHSCT
Donor Source: PMBC or BM
GVHD Prophylaxis Regimen: Calcineurin Inhibitor + MTX or MMF
Treatment Phase
RGI 100ug/kg IV infusion Days 0, 7, 14, 21, 28, 35 
Follow- up Phase 
until end of study or early termination
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 38 of 84 
to have a DLT among the first 3 subjects, consideration will be given to enrolling up to 3 
additional subjects. However, this decision will not be made solely on the observed occurrence 
(or lack of) DLTs; rather the SRC will consider the totality of the safety data before arriving at a 
definitive conclusion regarding enrollment of additional subjects at the dose of 100 μg  /kg. If 
within the first 3 subjects, 1 or more DLT s are observed, then consideration will be given to use 
of an alternative dose and/or dosing schedule, with the ultimate decision being made by the SRC. 
If an alternate dose and/or schedule is used, the same process as described above will be used.  If 
the additional 3 subject s (beyond the initial 3) are allowed to enroll at the dose of 100 μg  /kg or a 
lower dose and/or alternative schedule, safety data after the 6th subject has complete d all 6 doses, 
as well as initial efficacy,  PK and PD data will be evaluated in coming to a recommendation 
regarding proceeding to the Expansion Phase , with this recommend ation made by the SRC. Once 
the study extends to the Expansion Phase , enrollment will be open to all sites ( Figure 2).  
6.1.1 Definition of Dose -limiting Toxicities  
All subject s are expected to experience hematologic toxicity as part of the myeloablative 
alloHSCT procedure. Therefore, hematologic toxicit ies (e.g., leukopenia and thrombocytopenia) 
will not be useful measures of drug -induced toxicity, and DLTs are defined by non-hematologic 
toxicities.  
The following DLT criteria apply to the Safety Run-in Phase of the study. A DLT is defined as 
any treatmen t-relate d AE that is not attributable to an extraneous cause ( i.e., disease progression , 
preparatory regimen or HSCT infusion) and also excludes any signs and symptoms of GvHD. 
DLT is an adverse event  occurring in the period of 30 days after the first dose of RGI -2001 
administration , and meeting at least one of the following NCI CTC (Version  5.0) criteria:  
• Grade 3+ infusion- related /cytokine release reactions  
• Graft failure  (as defined in Section  9.4.1.) 
• Any Grade 4-5 non-hematologi cal AE  
• Delay in dosing by > 2 weeks due to treatment -related AE that is not attributable to an 
extraneous cause as defined above 
Subjects who do not complete the DLT window for reasons other than toxicity may be replaced. 
Similarly, if a subject receives ≤  50% of planned doses of RGI-2001 for reasons other than 
toxicity considered related to RGI- 2001, this subject may be replaced.  
Figure  2 DLT Schema  
 

 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 39 of 84 
6.2 Expansion Phase  
Once a dose/schedule is determined by the SRC to have an acceptable safety/PK profile, 
enrollment will continue in the Phase 2 Expansion Phase and be extended to all sites.  
Accrual is targeted at 50 subjects who receive the dose deemed as acceptable from the Safety 
Run-in Phase (44 in the Expansion Phase, 6 from the S afety Run-in P hase at the dose used in 
expansion). All subjects in the Expansion Phase who receive at least one dose will be considered 
in all efficacy and safety analyses.   
Subjects will receive open -label RGI -2001 at a dose of 100μg /kg (unless an alternative dose 
and/or schedule is chosen by SRC), via 30- minute intravenous (IV) infusion on a weekly basis 
for 6 doses (or an alternative dose/schedule as determined in the run- in phase) in addition to a 
SOC GvHD prophylactic regimen. The first dose will be administered on Day 0 at approximately  
30 minutes and no later than 1 hour after HSCT infusion. Subsequent doses will be administered 
weekly, on Days 7, 14, 21, 28 and 35. 
6.3 Control Group  
A non- randomized, contemporary control group from the CIBMTR database will be derived for 
comparison. Control subjects will be chosen so as to meet all eligibility requirements for the 
clinical trial, have received a transplant in the same time window as the study subjects, and have 
been transplanted in a center that participates in this study. Consent will be obtained via  the 
CIBMTR to participate in this study (Section 11). 
6.4 Safety Review Committee  
As noted above, a safety review committee will be used in this study. The SRC will serve  
3 primary roles: 1) assessment of DLTs , other safety measures, and PK/PD in th e initial 
3 subjects to determine whether dose and schedule appropriate to enroll another 3 subjects 
2) assessment of safety and PK/ PD data to determine  suitability to proceed to dose expansion 
3) ongoing monitoring of both safety and aggrega ted efficacy data. The SRC  will develop and 
follow a data and S afety Monitoring P lan and c harter.  
The SR C will be composed of, at a minimum the Sponsor  or designee me mbers including the 
Medical Monitor, Statistician , Safety Scientist, and the Lead Principal Investigator (PI). SRC 
meetings will occur in accordance with the SRC  charter.  
Depending on the results of safety reviews, the SRC may provide recomm endations on the future 
continuation of the study and other relevant steps, including prophylactic pre- medications in all 
or some current and future subjects.  
6.5 Number of Sites  
This study will be conducted at 8- 12 sites in the United States.   
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 40 of 84 
6.6 Number of Subje cts 
Anticipated  accrual  is 50 patients who receive at least one dose of RGI -2001, with at least 
6 subject s in the Safety R un-in Phase, and up to 44 subjects in the Expansion Phase. It is 
anticipated that a minimum of 250 subjects will be included in the control group. 
6.7 Study Duration  
Individual subject participation is expected to last up to one year  following allo HSCT , including 
a 6-week treatment period and a  42-week  follow-up period. In addition, there is a screening 
period lasting approximately 2 weeks.   
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 41 of 84 
7 SUBJECT POPULA TION  
7.1 Inclusion Criteria  
All subjects (including CIBMTR control group, except where noted) must meet the following 
criteria:  
1. Ages > 18 and ≤  65 years of age  
2. Has a h ematologic malignanc y as defined below and is considered a candidate for allo 
HSCT : 
a. Acute myelogenous leukemia (AML) in first or subsequent morphologic complete 
remission  
b. T or B cell a cute lymphoblastic leukemia (ALL) in first or s ubsequent complete 
morphologic remission  
c. Myelodysplastic syndr ome (MDS), chronic myelomonocytic leukemia (CMML), 
myeloproliferative disorder (MPD) including myeloid metaplasia and myelofibrosis  
and are currently with < 10% blasts in bone marrow  
d. CML subject s who have received prior treatment including at least one tyrosine 
kinase inhibitor and are currently in chronic phase or with a complete hematologic remission but with  evidence of cytogenetic or molecular relapse  
3. Must have adequate organ function as def ined below  (RGI -2001treatment group only): 
a. Cardiac function: Left ventricular ejection fraction at rest ≥ 45% 
b. Liver function: total bilirubin < 1.5 x upper limit of normal (ULN) ; alanine 
aminotransferase (ALT) and aspartate aminotransferase ( AST ) < 2.5 x t he ULN. 
Patients who have been diagnosed with Gilbert’s Disease or malignant involvement 
are allowed to exceed the defined bilirubin value of 1.5 x the ULN  
c. Serum creatinine < 2 mg/ dL or estimated  creatinine clearance >50mL/ min calculated 
using the Cockcroft-Gault equation 
d. Pulmonary: DLCO (corrected for hemoglobin) and/or FEV
1 ≥ 50 % 
4. Considered suitable candidate for a myeloablative allogeneic or unrelated donor transplant 
based on institutional criteria  
5. Subject must be receiving first allogeneic transplant from a single donor.  Prior auto logous 
transplant is acceptable  
6. Transpl ant Donor:  
a. Matched related donor (8/8): Molecular identity at HLA -A, -B, -C and - DRB1 by 
high-resolution typing 
b. Unrelated donor ( ≥ 7/8 allelic matc h): high resolution molecular typing at the 
following loci is required HLA -A, - B, -C and - DRB1  
c. Meets institu tional criteria for bone marrow or PBSC donation (see Section 7.4) 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 42 of 84 
7. Source of the Allograft:  
a. Unmodified bone marrow or mobilized peripheral blood ste m cell (PBSC) transplant, 
using granulocyte colony stimulating factor (G- CSF) as the mobilizing agent . Cord 
blood is not allowed 
8. KPS ≥  60 
9. Is a candidate for anti -graft -vs-host- disease ( GvHD) prophylaxis that includes: 
a. A calcineurin inhibitor (either tacrolimus [FK 506] or cyclosporine A), in 
combination with either methotrexate (MT X), mycophenolate mofetil (MMF)  
10. Ability to understa nd and willingness to sign a written informed consent form  
Inclusion criteria pertaining specifically for subjects scheduled to receive RGI -2001: 
11. If female of childbearing potential, must have had a negative serum pregnancy test prio r to 
enrollment and mu st have agreed to use a double barrier method of contraception for 
90 days following the last dose of R GI-2001 
12. If male, must be sterile or willing to use an approved method of contraception from the 
time of info rmed consent to 90 days after the last do se of RGI -2001  
7.2 Exclusion Criteria  
Any s ubjects (including CIBMTR control group) who meet any of the following criteria will be 
excluded from study entry: 
1. Has had any other prior organ transplantation  
2. Planned procedure to deplete regulatory T -cells from donor transplant materials  
3. Planned reduced intensity conditioning 
4. Planned use of any additional or alternative drug(s) for GvHD prophylaxis than listed in the inclusion criteria (e.g., rapamycin, cyclophosphamide, steroids )  
5. Has had prior treatment with anti- CD3, other T cell depleting antibodies, or 
anti-thymocyte globulin within 12 months prior to allo HSCT  procedure 
6. Is participating in a trial (other than RGI-2001-003) involving an investigational 
agent/non- standard of c are drug.  
7. Has progressive underlying malignant disease including post- transplant 
lymphoproliferative disease.  
8. Has evidence of active central nervous system (CNS) disease including known brain or 
leptomeningeal disease (CT or MRI scan of the brain required only in case of clinical suspicion of C NS involvement).  
9. Known history of human immunodeficiency virus (HIV) 
10. Active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV)  (control group 
only) 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 43 of 84 
11. Is female and pregnant or lactating  
12. Patients with active bacterial, viral or fungal infectio ns (currently taking medication(s) 
and with progression or no clinical improv ement)  
Exclusion criteria pertaining specifically  for subjects scheduled to receive RGI -2001: 
13. Has undergone major surgery within 1 month before Day 0. Indwelling catheter placement 
is allowed  
14. Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection with viral load above the 
limit of quantification .  Subjects that are on study with HBV or HCV infection should 
have titers checked regularly, as per institutional standard of care.  
15. Has had any other condition that, in the opinion of the Investigator, renders the subject unsuitable for study part icipation  
16. Has a documented history of uncontrolled autoimmune disease or on active treatment  
17. Vaccinated with live, attenuated vaccines within  4 weeks of first dose of study drug. 
18. History of myocardial infarction, unstable angina, or acute coronary syndrome within 
6 months prior to receiving study drug 
19. Has received an inve stigational agent within 4 half-lives or 14 days prior to HSCT , 
whichever is shorter  
7.3 Eligibility for the Control A rm 
Subject s in the control arm will be identified from subject s reported to the CIBMTR from U.S. 
centers and which agree to participate in this study . Control subject s must satisfy t he inclusion 
and exclusion criteria of this study according to S ection  7.  
Data for all eligible subject s in centers agreeing to participate in the study will be used to 
constitute the control database for this study.   
7.4 Donor Screening  
Stem cell or bone marrow donors will be evaluated according to institutional protocol. A bone 
marrow transplant physician and/or nurse practitioner will perform a complete medical history 
and physical exam, donor health history questionnaire and Zika virus screening. Required testing will include hematology studies, evaluation of risk for hemoglobinopathy as clinically indicated, 
chemistry studies, infectious disease testing, EKG, and chest x -ray. Bone marrow donors will 
also require evaluation and clearance by an anes thesiologist as per  institutional practices.  
Donors will be considered eligible if s creening shows that the donor is free from risk factors for, 
and clinical evidence of, infection due to relevant communicable disease agents and diseases, and is free from communicable di sease risks associated with transplantation  (test results for 
relevant communicable disease agents are negative or nonreactive).   
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 44 of 84 
7.5 Withdrawal/D iscontinuation  from Treatment, Procedures and S tudy   
7.5.1 Study Discontinuation  
The Sponsor has the righ t to terminate this study at any time.  Reasons for terminating the study 
overall or at a specific study site may include, but are not limited to the following:  
1. The incidence or severity of adverse events (AEs) in this or other RGI -2001 studies 
indicates a potential health hazard to subjects 
2. Subject enrollment is unsatisfactory  
3. Data recording is inaccurate or incomplete  
4. Investigator does not adhere to the protocol or applicable regulatory guidelines in 
conducting the study  
5. The safety review comm ittee (SRC) recommends termination of the study  due to revealed 
safety concerns.  
7.5.2 Subjects’ Decision to Withdraw  
Subjects have the right to withdraw from the study at any time and for any reason without 
prejudice to their future medical care by the physician or at the institution.  
Subjects can  decline to continue receiving investigational product and/or other protocol-required 
therapies or procedures at any time during the study but continue participation in the study. If this occurs, the investigator is to discuss with the subject the appropriate process for 
discontinuation from investigational product or other protocol- required therapies and must 
discuss with the subject the options for continuation of the Schedule of Assessments and 
collection of data, inc luding endpoi nts and adverse events.  The investigator must document  the 
level of follow -up that is agreed to by the subject (e.g., in person, by telephone/mail, through 
family/friends, in correspondence/communication with other physicians, from review of the medical re cords). 
Withdrawal of consent f rom a study means that the subject does not wish to receive further 
protocol-required therapies or procedures, and the subject does not wish to or is unable to continue further study participation. Subject data up to withdraw al of consent will be included in 
the analysis of the study, and where permitted, publicly available data can be included after 
withdrawal of consent. The investigator is to discuss with the subject appropriate procedures for 
withdrawal from the study.  
If a subject  fails to return  for scheduled  visits,  a documented effort  must  be made  to determine
 
the reason.  If the subject cannot be reached  by telephone after two attempts,  a certified  letter 
should be sent to the subject  (or the subject’s legally  authorized representative,  if appropriate) 
requesting contact with the Investigator.  Attempts  to contact  the subject should be documented in 
the study records. 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 45 of 84 
7.5.3 Discontinuation of Study T reatment  and/or W ithdrawal of Subjects Prior to Study 
Completion 
The investigat or and/or Sponsor  can decide to withdraw a subject(s) from investigational product 
and/or other protocol -required therapies, protocol procedures, or the study as a whole at any time 
prior to study completion.  Reasons for remo val from protocol-required inve stigational product or 
procedural assessments include any of the following: 
1. Subject withdrawal of consent   
2. Safety concern (e.g., due to an adverse e vent including those defined as DLT criteria , 
ineligibility determined, significant protocol deviation, nonc ompliance, requirement for 
alternative therapy, pregnancy)  
3. Death 
4. Lost to follow -up 
If a subject develops acute G vHD prior to completing all six RGI-2001 doses, the subject is still 
permitted to receive any remaining RGI-2001 doses with written approval by the Medical 
Monitor and if no experimental GvHD treatment is planned.  
Subjects who permanently discontinue RGI- 2001 prior to receiving all six doses  should be 
encouraged to remain in the  study and follow the SOA (s ee Section 3 ) for all remaining study 
visits  primarily for assessment of secondary endpoints. 
Subjects who are permanently disco ntinued from the study, either during the treatment period or 
follow up period, should complete the Early Termination Visit as per the SOA ( Section 3) and, if 
applicable, monitor adverse event through 30 days of last RGI-2001 dose. 
7.6 Replacement  of Subjects  
Subjects in the Safety R un-in Phase who do not complete the DLT window for reasons other 
than toxicity may be replaced. Similarly, if a sub ject in the Safety Run- in Phase receives ≤  50% 
of planned doses of RGI-2001 for reasons other than toxicity considered related to RGI-2001, 
this subject may be replaced.  All subjects who receive at least one dose of RGI -2001 in the 
Expansion Phase will be considered evaluable. 
Subjects who have c ancelled alloHSCT  will also be replaced . 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 46 of 84 
8 STUDY DRUG  
Refer also to the current sponsor approved study Pharmacy Manual for details. 
8.1 Physical Description  
 
  
 
8.2 Pa
ckaging and Labeling  
RGI-2001 for Injection  is supplied as a sterile  liquid  suspension  filled into depyrogenated USP 
Type 1 5-mL glass vials with a 2.5 mL fill volume, using a closure system consisting of 
sterilized rubber stoppers (22 mm) with aluminum royal blue sea ls and flip -off caps. The dosing 
is based  on the dose of the liposome- encapsulated  ingredient, RGI7000. Each  vial contains 
5 mg/mL  of RGI 7000 and 50 mg/mL  of lipid blend in a 10% sucrose solution containing  
20 mM Histidine.   
The product is for single-use only and does not contain  a preservative. 
8.3 Storage 
RGI-2001 should be stored  at 2°–8°C,  protected  from  freezing  and exposure to light. 
8.4 Study Drug Accountability  
The PI or designee is responsible for maintaining accurate records (including dates and 
quantities) of IP received, subjects to whom IP is dispensed (subject -by- s ubject dose specific 
accounting), and IP lost or accidentally or deliberately  destroyed. The PI or designee must 
retain  all unused or expired  study supplies until a Sponsor-designated Clinical Research  
Associate (CRA)  has confirmed  the accountability data.    
8.5 Return and Disposition of Study D rug 
Unused study drug must be kept in a secure location for accountability  and reconciliation  by the  
Sponsor -designated CRA.  The Investigator or designee must  provide an e xplanation for any 
destroyed or missing  study  drug or study materials.  
Unused study drug may be destroyed on site, per the site’s  standard  operating procedures, but  
only after Sponsor or its designee has granted approval for drug destruction. The 
Sponsor -designated CRA must account for all study drug in a formal reconciliation  
process prior  to study drug destruction. All onsite study drug destruction  must be documented. 
Documentation must be provided to the Sponsor or its designee and the original retained  in 
the PI’s study  files.  If a site is unable to destroy  study drug appropriately, the site can return 
unused study  drug to Sponsor ’s designee upon request.  

 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 47 of 84 
All study drug and related  materials  should be stored, inventoried, reconciled,  and destroyed  or 
returned,  according to applicable  state and federal  regulations and study procedures.  
8.6 Administration and Dosing R egimen  
All subjects will receive 6 weekly doses of RGI -2001 100 μ g/kg via IV administration over 
30 minutes.  Weight should be taken within one day of dosing and the dosage of RGI-2001 
should be verified to be the same as the planned dose. The  dosage of RGI -2001 will be diluted in  
50 ml 0.9% normal salin e and the first dose w ill administered intravenously  at approximately  
30 minutes and no later than 1 hour after completion  of the allogeneic HSCT  on Day 0 (study 
Day 1  if transplant occurs over 2 days) . If cytokine release/infusion reaction is observed during 
or after HSCT, then RGI -2001 should be postponed until at least 30 minutes after the reaction 
has resolved. Subsequent RGI -2001 administrations  should be administered on Days 7,  14, 21, 
28, and 35 + /- 1 day. Pre-medications should not be administered prophylactically . However, if 
a grade 2 cytokine release is observed, pre- medication with an antihistamine (e.g ., 
diphenhydr amine ), an anti -pyretic  (e.g. acetaminophen) and corticosteroids (e.g., 4 mg 
dexamethasone or equivalent) should be administered. Consideration may be made to administer 
premedication  for Grade 1 cytokine release, depending on the constellation of symptoms. In 
addition, the SRC may recommend pre -medications in all current and future subjects depending 
on safety reviews.  
8.7 Randomization and Blinding  
This is an open -label study and there is no randomization or blinding. 
8.8 Prior  and Concomitant Medications 
Please see exclusion criteria for prohibited medications.  
Concomitant medications  are any prescription or over-the-counter preparations used from 
2 days prior to the preparatory regimen before Day 0 through the end of the subject’s study 
participation.  
Standard myeloablative preparator y regimens, (i.e., reduced intensity conditioning, non 
myeloablative conditioning, experimental regimens or drugs are not allowed), HSCT and 
standard supportive care/ prophylactic treatments (including but not limited to colony stim ulating 
factors, transfu sions, antibiotics/anti -virals/anti -fungals) per institutional guidelines for optimal 
medical care shall be permitted during participation of this study . The dose of steroids that are 
required for reasons unrelated to the underlying malignancy or HSCT proc ess or sequelae must 
not be higher than physiologic doses (the equivalent of 20 mg/day of prednisone). No anti -
thymocyte globulin (ATG)  is allowed in the conditioning regimen. 
GvHD prophylaxis must consist of a calcineurin inhibitor (cyclosporine or tacrol imus) in 
combination with MTX or MMF. Dosing, schedule and monitoring of the GvHD regimen should 
follow institutional guidelines.  Please see respective prescribing information for safety  
information. Steroids, sirolimus, post-transplant cyclophosphamide, A TG, other GvHD 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 48 of 84 
prophylactic agents (including investigational agents) or manipulation of the graft to reduce 
GvHD are not allowed.  
Post transplant maintenance therapy that inc ludes an investigational agent , or any treatments that 
can be used for GvHD are not allowed. Maintenance therapy for actionable targeted mutations 
(e.g., FLT3 inhibitors) or with FDA approved agents in any indication should not be initiated 
prior to Day 42 post allo HSCT.  
Treatment of GvHD should follow institutional guidelines and may  include steroid treatment at 
supra-physiologic doses. See Section  7.5.3 for development of GVHD prior to completion of 
RGI-001 dosing. 
The investigator may prescribe  additional medications during the study, as long as the prescribed 
medication is not  prohibited by the protocol. In  the event of  an emergency, any needed 
medications may be  prescribed without prior approval, but the  Medical Monitor must be  notified 
of the use of any medications, except acetaminophen, immediately  after use. Any concomitant  
medications  added or discontinued during the study  should be recorded  on the electronic case 
report form (e CRF. ) 
8.9 Dietary  or Other  Protocol Restrictions  
Dietary restrictions per institutional guidelines (e.g. neutropenic diet) may be  imposed  on study 
subjects.  Alcohol and tobacco use should be limited as per institutional guidelines.  
8.10 Dose Modification /Treatment Cessation  
If a subject permanently discontinues treatment in the Safety Run -in or Expansion Phase as 
specified below, s ee Sec tion 7.5.3 Discontinuation of Study Treatment and/or Withd rawal of 
Subjects Prior to Study Completion, for further details. 
8.10.1 Safety Run- in Phase  
RGI-2001 will be administered at a dose of 100 μg/kg IV weekly for 6 doses. There a re no dose 
reductions or escalations in this portion of the study except as recommended by the SRC at the 
end of the run-in period. Each individual infusion is allowed to be delayed up to 2 weeks for 
ongoing grade 3+ AEs, regardless of causality. However, i f a subject enrolled in the run -in 
period is not able to receive at least 50%  of RGI -2001 doses during the DLT window for reasons 
other than toxicity, then that subject will be replaced. Subjects requiring delay of an infusion of > 2 weeks should be discontinued from treatment.  
Subjects enrolled in the Run-in Phase beyond the DLT window who meet DLT criteria should be 
discontinued from study treatment. Supportive care should be administered as appropriate. 
8.10.2 Expansion Phase 
RGI-2001 will be administered at the dose and schedule agreed upon by the SRC at the 
completion of the Safety Run- In Phase. No dose escalations will be allowed.  
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 49 of 84 
If a subject has a treatment related Grade 3 adverse event (excluding any hematologic AE or 
CRS ) that is not considered to be related to extraneous cause ((i.e . disease progression, 
preparatory regimen, HSCT infusion), subsequent doses will be held until the toxicity returns to 
≤ Grade 2 or baseline.  RGI -2001 may be restarted at a dose of 10 µg/kg  IV infusion. 
Subjects who m eet DLT criteria (including Grade 3+ CR S) at any point in the study should be 
permanently discontinued from study treatment. Supportive care should be administered as appropriate. 
If subject has a 2
nd occurrence of Grade 3 adverse event, RGI-2001 will be held until the toxicity 
return s to ≤  Grade 2 or baseline.  RGI -2001 will be restarted at a dose of 1 µg/kg  IV infusion. 
If a subject experiences a G rade 4 adverse event that is related or continues to have recurrence of 
Grade 3 adverse events beyond the 2nd instance, discontinue RGI -2001 per manently.  
If a subject does not demonstrate evidence of myeloid engraftment by  Day 28, discontinue 
RGI-2001 permanently. 
8.11 Management of Cytokine Release Syndrome 
Pre-medications for RGI-2001 will not be administered initially  as no signs of cytokine release 
were observed in the Phase 1 study . If symptoms suggestive of cytokine release (fever,  chills,  
etc.) are observed  with administration  of RGI-2001, subjects should be treated according to 
institutional guidelines. The SRC may provide additional recommendations for such 
situations (please refer to S ection 6.4). For Grade 2 AEs, acetaminophen, diphenhydramine 
and/or steroids may be administered. Premedication  for subsequent RGI -2001 infusions may 
consist of intraven ous or oral  dexamethasone  (4 mg), acetaminophen and diphenhydramine prior  
to each administration  of RGI-2001. Details should be discussed with the Medical Monitor prior 
to the next infusion. For subjects with G rade 3–4 infusion reaction/cytokine release 
symptoms should be discontinued from further RGI -2001 therapy regardless of whether 
prophylactic treatment was administered.  
Table  1 M edical Guidelines for C ytokine R elease Reactions 
Grade 1  • Continue to monitor subject carefully.  
• No treatment is needed  unless symptoms worsen  
• Consider pre-medications for subsequent infusions depending on the 
presentation.  
Grade 2  • Hold infusion until symptoms resolve.  
• Supportive care as per institutional guidelines. May include but not limited to 
acetaminophen, diphenhydramine, H2 blockers, dexamethaso ne or equivalent , 
oxygen, demerol or equivalent, IV fluids, anti -emetics   
• For subsequent RGI-2001 infusions, premedicate with acetaminophen, diphenhydramine, dexamethasone  4mg or equival ent 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 50 of 84 
Grade 3-4 • Discontinue RGI -2001 treatment  
• Supportive care as per institutional guidelines. May include but not limited to 
acetaminophen, diphenhydramine, H2 blockers, dexamethasone or equivalent, oxygen, demerol or equivalent, IV fluids, anti -emetics, vasopressors, 
mechanical ventilation.  
 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 51 of 84 
9 STUDY ASSESSMENTS AND PROCEDURES  
The Schedule of Assessments in S ection  3 describes the frequency and timing of the study 
assessments and procedures. The schedul e of PK and PD sample collection is provided in 
Appendix 1. All enrolled subjects will undergo the same study procedures unless otherwise 
noted. 
All screening evaluations must be completed and reviewed to confirm a potential subject  meet s 
all eligibility criteria  prior to alloHSCT, including the preparatory regimen. Investigators are to 
maintain a screening log of all potential subject s.  
Screening assessments must be performed within 14 days prior to initiation of a ny 
treatments  related to the HSCT including the preparatory regimen  unless otherwise specified.  
Informed consent, screening hepatitis , HIV tests, and tumor assessment (provided that no 
intervening therapy for their malignancy has been administered) may be obtained up to 42 days 
before the preparatory regimen.  PFTs and ECHO may be obtained as per institutional standard 
of care criteria within 84 d ays prior to the preparatory regimen provided no intervening therapy 
for their malignancy has been administered. Pregnancy test must be conducted within 7 days 
before preparatory regimen.  Standard of care tests/procedures, performed prior to the subject 
signing the informed consent form (ICF) can be used as part of the screening assessments as long 
as the tests/procedures are performed within the appropriate  screening window. Screening 
assessments do not need to be repeated due to minor delays in procurement of donor HSC’s. 
9.1 General Study Procedures 
9.1.1 Informed C onsent  
Except as noted in Section 9, informed consent must be obtained before conducting any study-
specific activities/procedures and documented in the subject ’s source documents. 
9.1.2 Demographics 
Subject demographics (including date /year  of birth, sex, race, ethnicity, and age at the time of 
consent) will be collected. 
9.1.3 Medical/Cancer/Surgical  History  
A complete medical , cancer  and surgical history starting prior to enrollment through the time of 
consent w ill be obtained from each subject at the Screening visit.  
Prior cancer history includes : (i) date of diagnosis, (ii) prognostic score if applicable  (iii) all 
previous therapies ( i.e., chemotherapy, immunotherapy, biologic or targeted agents, experimental 
therapies, radiotherapy, and surgery), (iv)  previous therapy details ( i.e., regimen, sta rt and stop 
dates),  (v) best response for each regimen  
Data from SOC procedures will be part of the subject 's medical history and may be used for 
study purposes. 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 52 of 84 
9.2 Efficac y Assessments  
Efficacy evaluations will be performed as described below. Refer to the SoA, Section  3 for the 
timing of all efficacy evaluations.  
9.3 Evaluation of GvHD  
The frequency of acute and chronic GvHD will be assessed in both parts of the study. 
Assessment for GvHD should be performed during every examination or per institutional 
guidelines from the time  of engraftment to end of study. Documentation of t he timing, severity 
treatment for GvHD and outcome including any biopsies should be obtained at regular intervals 
per the SoA.  
The clinica l activity of RGI-2001 will be evaluated by assessment of GvHD according to the 
MAGIC Criteria and Modified Keystone Criteria for grading acute  GvHD (Appendix 2 and 
Appendix 3)  NIH 2014 criteria will be used to assess chronic GvHD. 
9.3.1 Tumor Assessment  
Evaluation of status of hematologic malignancy should be conducted as per institutional 
guidelines but should include a bone marrow aspirate and biopsy with cytogenetics, molecular 
diagnostics and chimerism as appropriate based on disease histology.  
  
 
 
 
 
 
 
 
  
 
 
 
 
  
  
  

 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 53 of 84 
 
  
 
 
 
 
9.4
 Safety Assessments  
Safety  will be assessed  by clinical  laboratory studies , time to myeloid and platelet engraftment 
and by monitoring  of AEs.  
Potential safety  issues  associated  with the route of administration  or the pharmacology of 
RGI-2001 include hypersensitivity  to RGI-2001, organomegaly, microgranuloma, and 
infections. Subjects will be monitored  closely for hypersensitivity reactions to  RGI-2001. 
Infections will be recorded throu ghout the study. Subjects will be followed for 30 days 
following end of treatment and monitored for the occurrence of adverse events by means  of 
physical examination, and laboratory  testing, including hematology, T- cell, 
immunophenotyping, other  serum  chem istry,  urinalysis  and liver function  tests.  
9.4.1 Marrow  Engraftment  and Graft  Failure  
Myeloid engraftment  will be defined as the first of  3 consecutive days when  the absolute 
neutrophil counts (ANC)  exceeds 0.5 x109/L and  platelet engraftment  will be  defined as the first  
of 3 consecutive days  when  the platelet  count exceeds 20 x x109/L without transfusion  support. 
Graft failure  will be defined as the lack of myeloid engraftment in  subject s surviving in  
remission for at  least 28 days after  transplantation .  
9.4.2 Dose Limiting Toxicities  
Subject s enrolled in the Safety Run- in Phase will be monitored for DLTs ( Section 4.1 ).  
9.4.3 Adverse Events 
Information regarding AEs and SAEs will be collected as per Section 10. 
9.4.4 Concomitant Medications   
Concomitant medications will be documented for each subject  at each scheduled visit.  All 
concomitant medications includin g prescription  or OT C preparations used from 2 days prior to 
the preparatory regimen  before Day 0 through the end of the subject’s  study  participation, 
including changes is medication, should be recorded. 

 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 54 of 84 
9.4.5 Weight and Height  
Weight (indoor clothing without shoes) in kilograms , should be taken within 1 day of dosing and 
the dosage of RGI -2001 should be verified to be the same as the planned dose. Height (without 
shoes) in centimeters,  should be obtained prior to initia tion of the preparatory regimen only.  
9.4.6 Physical Examinations, Vital Signs and Karnofsky Performance Status  
A complete physical e xamination will be performed by the investigator or designee at time 
points specified in the Schedule of Assessments Sectio n 3. Examination at screening should 
include HEENT, dermatologic, cardiovascular, respiratory, GI (includ ing assessments of liver 
and spleen), musculoskeletal, neurological, and lymphatic systems.  Physical examinations at all 
other time points  should be limited,  symptom- directed physical examinations of an AE or 
SAE ,  including body systems as appropriate.  
Please also  refer to Efficacy Assessments Section  9.3 for description of MAGIC and Modified 
Keystone Criteria  symptom assessments for GvHD. 
Vital signs and KPS will be performed as indicated in the SoA. Vital signs including  systolic 
and diastolic blood pressure (BP), body temperature, heart  rate, and respiratory rate should be 
taken in supine or seated position . Vital signs should be obtained within 15 minutes prior to 
RGI-2001 infusion and should be repeated within 30 minutes af ter the infusion. Additional vital 
signs measurements should be obtained as clini cally indicated.   
KPS will be  assessed as per  Appendix 5. 
9.4.7 Electrocardiogram   
A single, 12- lead ECG will be performed at the time point specific in the SoA (Section   3). 
The subject must be in a supine position in a rested and calm state for at least 5 minutes before 
ECG assessment is conducted.  If the subject is unable to be in the supine position, the subject 
should be in the most recumbent position possible.  
The e lectrocardiogram should be performed in a standardized method, prior to blood draws or 
other invasive procedures. The  ECG must include the following measurements: QRS, QT, QTc  
using Fr edericia’s f ormula , RR, and  PR intervals. If the ECG is abnormal, including QTc >450 
msec, perform in triplicate approximately 30 seconds apart , and record  the average of the three  
readings. 
The PI  or designated site physician will review all ECGs. Standard ECG machines should be 
used for all study -related ECG requiremen ts.  
9.4.8 Clinical Laboratory A ssessments  
Blood samples for safety laboratory tests, which include clinical chemistry, hematology and 
coagulation, will be collect ed according to the SoA ( Section  3). Additional laboratory 
assessments include pregnancy test, hepatitis B and C testing.  All clinical laboratory analyses 
will be performed by the site local laboratory unless otherwise indicated. Reference ranges will  
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 55 of 84 
be supplied by the laboratory and used t o assess the data for clinical significance and out -of-
range values. Biomarker and pharmacokinetic samples will be shipped to a specialty  laboratory. 
Screening laboratory assessments used to determine subject eligibility may be repeated once (u p 
to a total of 2 times during the 14 day screening period), if necessary.  
Clinical laboratory tests will be performed as indicated in Table  2: 
Table  2 Clinical Laboratory Tests 
Chemistry  Coagulatio n  Urinalysis  Hematology  Other Labs  
Sodium  
Potassium  
Chloride  
Bicarbonate  
Total protein  
Albumin  
Calcium  
Magnesium  Phosphorus  
Glucose  
BUN or Urea  
Creatinine  
Total bilirubin  
Direct bilirubin  
Alk phos  
LDH  
AST  
ALT  
GGT  PT/INR aPTT or 
PTT  
  Specific gravity pH  
Blood  
Protein   
Glucose  
Bilirubin  
Ketones  
Urobilirubin  
  RBC  
Hemoglobin Hematocrit  
Platelets  
WBC  Differential  
Neutrophils  
Eosinophils  Basophils  
Lymphocytes  Monocytes  
Blasts    Hep B surface antigen  
Hep C antibody  
Hep B total core 
antibody  
Hep B viral load  
Hep C viral load  
Pregnancy test  
Bone marrow aspirate 
and biopsy  
Cytogenetics  
Molecular markers 
Chimerism 
  
  
Immunophenotyping  
 
Alk phos : ALT: alanine transaminase; AST: aspartate transaminase; BUN: blood ure a nitrogen; GGT:  gamma -
glutamyl transferase;  LDH: lactate dehydrogenase; PTT: partial thromboplastin time; PT: prothrombin time; aPTT: 
abbreviated partial prothromb oplast in time; RBC: red blood cell; WBC: white blood cell  
The maximum amount of blood collected from each subject over the duration of the study, 
including any extra assessments that may be required, will not exceed  local guidance/regulations. 
Repeat or unscheduled samples may be taken for safety reasons or for technical issues with the samples. Further information around blood volumes can be found in the Laboratory Manual.  
Any abnormal clinical laboratory test results that lead to a change in subject management 
(ie dose dela y, clinical condition, need for additional medication or monitoring) are  considered 
clinically significant. The  diagnosis, if known, associated  with abnormalities  in clinical  
laboratory  tests that are
 considered  clinically  significant by the Investigator  will be recorded  on 
the AE eCRF. Any abnormal clinical laboratory test re sult determined  to be clinically significant 
by the Investigator should be repeated (at the Investigator’s discretion) until the cause of the 

 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 56 of 84 
abnormality is determined, t he value returns to baseline or to within normal limits, or the  
Investigator determine s that the abnormal value is no longer clinically  significant.  
9.4.8.1 Donor/Host Chimerism  
Donor/host chimerism for the evaluation of engraftment status of the stem cell transplantation 
will be evaluated at the local laboratory. 
9.4.8.2 Pregnancy Testing 
A serum pregnanc y test will be performed on each female subject  of childbearing potential at the 
screening visit . A negative pregnancy test must be documented prior to administration of study 
drug. 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 57 of 84 
10 ADVERSE EVENTS  
10.1 Definitions  
According to the ICH guideline for Good Clinica l Practice, an AE is any untoward medical 
occurrence in a patient or clinical investigation subject  administered a pharmaceutical product  
and which does not necessarily have a causal relationship with this treatment. An AE can 
therefore be any of the follo wing: 
• Any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal 
(investigational) product, whether or not considered related to the medicinal (inves tigational) product  
• Any new disease or exacerbation of an existing disease (a worsening in the character, frequency, or severity of a known condition),  
• Recurrence of an intermittent medical condition (e.g., headache) not present at 
baseline  
• Any deterioration in a laboratory value or other clinical test (e.g., ECG, X- ray) that is 
associated with symptoms or leads to a change in study treatment or concomitant treatment or discontinuation from study drug  
• AEs that are related to a protocol-mandated intervention, including those that occur 
prior to assignment of study treatment (e.g., screening invasive procedures such as 
biopsies) 
10.1.1 Serious Adverse Event  
A serious adverse event is any adverse event that at any dose meets any of the following criteria:  
• Fatal  (i.e., the adverse event actually causes or leads to death)  
• Life threatening  (i.e., the adverse event, in the view of the Investigator, places the 
patient at immediate risk of death). This does not include any adverse event that had it 
occurred in a more severe form or was allowed to continue might have caused death.  
• Requires inpatient hospitalization  or prolongation of existing hospitalization 
• Results in persistent or significant disability/incapacity  (i.e., the adverse event 
results in substantial disruption of the patient’s ability to conduct normal life 
functions)  
• Congenital anomaly/birth defect in a neonate/infant born to a mother exposed to 
study drug  
• Significant medical event.  An important medical event is an event that may not 
result in death, be life-threatening, or require hospitalization but may be considered an SAE when, based upon appropriate medical judgment by the Investigator or the 
Sponsor, it may jeopardize the patie nt and may require medical or surgical 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 58 of 84 
intervention to prevent one of the outcomes listed i n the definitions for SAEs. 
Examples of such medical events include second primary malignancies developed 
months after the end of the study treatment, or convulsions that do not result in in - 
patient hospitalization . 
The terms “severe” and “serious” are no t synonymous. Severity refers to the intensity of an 
adverse event (rated as mild, moderate, or severe, or according to NCI CTCAE criteria  v. 5.0; 
see Section 10.2.2); the event itself may be of relatively minor medical signific ance (such as 
severe headache without any further findings).  
Severity and seriousness need to be independently assessed for each adverse event recorded on 
the e CRF . 
10.2 Adverse Event  Reporting  
The reporting period for non- serious adverse events starts at the commencement of the infusion  
of RGI -2001 on Day 0 and continues for at least 30 days following the last dose of study drug. 
Medical conditions that start after the ICF is signed, but before the first dose of study drug should be recorded on the medical his tory eCRF.  
If an AE remains unresolved 30 days following the last dose of study drug, the subject will be followed, at the investigator’s discretion, until resolution of the event. Resolution is defined as return to baseline status or stabilization of the condition with the expectation that it will remain 
chronic. 
Adverse events (including laboratory abnormalities that constitute AEs) should be described 
using a diagnosis whenever possible, rather than individual underlying signs and symptoms. 
When a clear diagnosis cannot be identified, each sign or symptom should be recorded as a 
separate AE.  
The Investigator should ask the subject  non-leading questions to determine if any AEs have 
occurred during the study, since the last study visit. Adverse events may a lso be recorded when 
they are volunteered by the subject , or through physical examination, laboratory tests, or other 
clinical assessments.  
10.2.1 Laboratory Test Abnormalities  
Laboratory abnormalities that constitute an AE in their own right (i.e., are considered to be clinically significant, induce clinical signs or symptoms, require concomitant therapy, or require changes in study drug), should be recorded on the Adverse Event s eCRF . Whenever possible, a 
diagnosis, rather than a symptom should be provided (e.g., anemia instead of low hemoglobin). 
Laboratory abnormalities that meet the criteria for an AE should be followed until they have 
returned to baseline levels (as measured  during the Screening visit) or an adequate explanation of 
the abnormality is identified. When an abnormal laboratory or test result corresponds to a sign/symptom of an already reported AE, it is not necessary to separately record the laboratory/test result as an additional event.  
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 59 of 84 
Not every laboratory or ECG abnormality qualifies as an AE. A laboratory or ECG test result 
must be reported as an AE if it meets any of the following criteria:  
• Accompanied by clinical symptoms 
• Results in a change in study treatment (e.g., dosage modification, treatment interruption, or treatment discontinuation) 
• Results in a medical intervention (e.g., potassium supplementation for hypokalemia) or a change in concomitant therapy 
• Clinically significant in the Investigator’s judgme nt 
It is the Investigator’s responsibility to review all laboratory abnormality . Medic al and scientific 
judgment should be exercised in deciding whether an isolated laboratory abnormality should be classified as an AE.  
If a clinically significant laboratory or ECG abnormality is a sign of a disease or syndrome (e.g., alkaline phosphatase an d bilirubin 5 × the ULN associated with cholecystitis), only the 
diagnosis (i.e., cholecystitis) should be recorded on the AE eCRF. 
If a clinically significant laboratory  or ECG abnormality is not a sign of a disease or syndrome, 
the abnormality itself sho uld be recorded on the AE eCRF, along with a descriptor indicating if 
the test result is above or below the normal range (e.g., "elevated potassium," as opposed to 
"abnor mal potassium"). If the laboratory abnormality can be characterized by a precise clinical 
term per standard definitions, the clinical term should be recorded as the AE. For example, an 
elevated serum potassium level of 7.0 mEq/L should be recorded as “hype rkalemia.”  
10.2.2 Adverse Event Severity  
The term “severe” is used to describe the intensity of an AE; the event itself could be of 
relatively minor clinical significance (e.g., ‘severe’ headache). This is not the same as a “serious” AE. 
The severity of the AE wi ll be graded by the Investigator according to the NCI CTCAE Grading 
Scale, v.5.0  
https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_R
eference_8.5x11.pdf 
If there is not a specific  NCI CTCAE grading scale for an AE, the severity will be characterized 
as mild, moderate, severe, or life -threatening, according to the following definitions: 
Grade  Descr iption  
1 (Mild)  Asymptomatic or mild symptoms, clinical or diagnostic observations 
only, intervention not indicated No  limitation  of usual  daily activities  
2 (Moderate)  Some  limitation  of usual  daily activities  
Minimal, local or non invasive  intervention indicated, limiting 
instrumental activities of daily activities  
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 60 of 84 
Grade  Descr iption  
3 (Severe)  Severe o r Medically significant but not immediately life threatening, 
hospitalization or prolongation of hospitalization indicated, disabling. 
Intervention typically  required.  
4 (Life Threatening)  Events that are considered life -threatening, urgent intervention 
indicated  
5 (fatal)  Death*  
*Grade 5 events must be reported as SAEs ( see Section  10.3.1  for reporting instructions), per the definition of an 
SAE in Section  10.1.  
10.2.3 Adverse Event Causality  
The Investigator should use their knowledge of the study subject, the circumstances surrounding 
the event, and an evaluation of any potential alternative causes to determine whether or not an 
adverse event is considered to be related  to the study drug. The following guidance should be 
taken into consideration. Discuss with medical monitor if needed:   
• Temporal relationship of event onset to the initiation of study drug  
• Course of the event, considering especially the effects of dose reduction, 
discontinuation of study drug, or reintroduction of study drug (where applicable)  
• Known association of the event with the study drug or with similar treatments  
• Known association of the event with the disease under study  
• Presence of risk factors in the patient or use of concomitant medications known to increase the occurrence of the event  
• Presence of non -treatment-related factors that are known to be associated with the 
occurrence of the event  
Relationship  Descri ption  
Not Related  Exposure to th e investigational product has not occurred, or the occurrence of 
the AE is not reasonably related in time, or the event is readily and more likely 
explained by the subject’s clinical state or by other modes of therapy administered to the subject.  
Note: per  your institution standard, if relationship is determined to be unlikely, it 
should be classified as Not Related unless the investigator determines possibly 
related or probably related are more appropriate with the definitions below.  
Possibly Related  The administration of the IP and the occurrence of the AE are reasonably related 
in time, and  
The AE could be explained equally well by factors or causes other than exposure to the IP.  
Follows a reasonable temporal sequence from study drug administration; but could have been produced by the subject’s clinical state or by other modes of 
therapy administered to the subject.  
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 61 of 84 
Relationship  Descri ption  
Probably Related  The study treatment and the AE were reasonably related in time,  
and the AE is more likely explained by exposure to the study product than by 
other causes, or the investigational product was the most likely cause of the AE  
10.3 Serious Adverse Events 
SAEs that occur at any time between the signing of the ICF  up to the first dose of study drug 
must be reported (in addition to SAEs that occur after the first dose of study drug).  
Important medical events that may not result in death, are not life -threatening, or do not require 
hospitalization may be considered SAEs when, based on appropriate medical judgment, they 
may jeopardize the subject and may require medical or su rgical intervention to prevent one of the 
outcomes listed in this definition. See definition of SAE in Section 10.1. 
Elective hospitalizations to administer, or to simplify trial treatment or trial procedures (e.g., an overnight stay to facilitate 24 -hour urine collection) or other medical procedures are not 
considered SAEs. A ‘serious’ hospitalization is defined as any inpatient hospital admission into 
the ward on the floor that includes a minimum of an overnight stay in a health care facility. An 
emergency room visit is not considered a hospitalization unless it results in an official admission 
as an inpatient to the hospital (e.g., undesirable effects of any administered trea tment) and must 
be documented as an SAE.  
10.3.1 Serious Adverse Events Reporting 
SAEs that occur at any time between the signing of the ICF until at least 30 days after  the subject  
has st opped study drug must be reported regardless of the casual  relationship to t he study drug.  
SAEs will  be reported immediately  (within 24  hours of learning  of the  event)  to the Sponsor or 
its designee by email  using the study- specific SAE  Report Form and recorded in the eCRF . In 
addition to  the outcome of the SAE,  any medication  or other therapeutic  measures used  to treat  
the event  will be recorded  on the appropriate  eCRF  page(s). Investigators  should not wait to 
collect  additional information  that fully  documents the event
 before notifying Sponsor or its  
designee of  an SAE.  Sponsor may  be required to report certain  SAEs  to regulatory  authorities 
within  7 calendar  days of  being notified  about the event; therefore,  it is important that  
Investigators submit additional information  requested  by Sponsor or its  designee as soon as it 
becom es available.  
Reporting of SAEs  to the IRB will be done in compliance with the standard operating 
procedures and policies of the IRB and with applicable regulatory  requirements.  Adequate  
documentation must be obtained by Sponsor or its  designee showing that the IRB was properly  
and promptly  notified  as required. 
The SAE  form should be em ailed  to: sae.regimmune@clindatrix.com  
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 62 of 84 
The Investigator is encouraged  to discuss with the medical  monitor any AEs for which the issue  
of seriousness is unclear or questioned. Contact information  for the M edical  Monitor is as 
follows:  
 
 
 
Any SAE observed after the 30- day follow -up period should only be reported to the Sponsor if 
the Investigator su spects that the SAE has a causal relationship to the study drug. An SAE should 
be followed until its resolution or until it is judged to be stable . An assessment should be made at 
each study visit (or more frequently, if necessary) of any changes in severity of the event, the 
suspected relationship to the study drug, the interventions required to treat the event, and the 
outcome of the event. 
Recurrent episodes, complications, or progression of the initial SAE must be reported, as 
follow -up to the original episode, within 24 hours of the Investigator receiving the follow-up 
information. 
10.4 Reporting of Dise ase Progression  
Progression of the malignancy/disease (including fatal outcomes) should NOT be reported as an 
SAE during the study or within the safety repor ting period . Any sudden or unexplained death 
should be reported as an SAE. However, the underlying disease or condition, which led to the fatal outcome, should be used as an SAE term. Death as an SAE term should be avoided, with the exception of rare situations when the cause of death is unknown. I f there is any uncertainty 
about a finding being due solely to progression of malignancy/disease, the finding should be reported as an AE or SAE, as appropriate. 
10.5 Reporting of GvHD  
The event of GvHD disease is a cr iterion for assessment of clinical activity and is therefore not 
considered to be an AE. GvHD should be reported within the eCRF . AEs and SAEs that occur in 
relation to GvHD that are not consistent with the nature and natural progression of the subject ’s 
disease should be recorded as AE/SAE. Death due to GvHD  that is consistent with the nature and 
natur al progression of the subject ’s disease is not recorded as an AE/SAE.   
10.6 Medication Errors 
Any dose or route of administration of RGI-2001 that was not administered as prescribed in the 
protocol should be reported as an AE in the eCRF regardless of whether or not there is an 
associated AE. Medication errors that meet the definition of a n SAE will be reported per the 
SAE reporting guidelines.  

 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 63 of 84 
10.7 Pregnanc y 
Although pregnancy is not considered an AE or SAE, all pregnancies occurring in subjects 
enrolled in this st udy or in a female partner of a male subject in this study must be reported to the 
Sponsor within 24 hours of becoming aware, and followed to outcome, even after the end of the 
study. I f a female subject inadvertently becomes pregnant while on study treatment, the subject 
will immediately be removed from the study. Any  pregnancies that occur within 150 days for 
females or 90 days for males following  the last dose of study treatment must be reported to the 
Sponsor.  
Refer to  Appendix 6 for complete  information regarding pregnancies including highly effective 
contraceptive methods and recording and reporting guidelines in the event of a pregnancy. 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 64 of 84 
11 REGISTRATION OF CIBMTR SUBJECTS FOR THE CONTROL GROUP  
This clinical trial will compare certain outcome parameters from subject s enrolled in the 
RGI-2001 treatment study to a contemporaneous control group obtained from the CIBMTR. 
(refer to  Section 12) 
11.1 Selection of Control Arm Transplant  Centers  
The CIBMTR will be contracted with the Sponsor to provide transplant subject data for the 
control group. Only CIBMTR research centers participating in the treatment protocol with 
experience in submitting comprehensive report forms to the CIBMTR will be eligible to participate in the study. Additionally, participating centers will need to agree to participate in this 
study and submit all CIBMTR report forms required for this study according to the CIBMTR 
pre-specified time schedule.  
11.2 Enrollment P rocedure for the Transplant S ubject s in the Control A rm via the 
CIBMTR  
Data reported on pre- transplant Transplant Essential Data (TED) forms to the CIBMTR by 
participating centers will be monitored to screen subject s who fulfill the eligibility criteria  
(Section 7). Control subject s who fulfill eligibility criteria and who have a signed ICF to allow 
their data to be used for research wil l be assigned to the CIBMTR comprehensive data reporting 
track (CRF -track) and cent ers will be notified. Forms due requirements for the case report form 
(CRF ) track will be implemented.  
It is anticipated that a minimum of 250 transplant  subject s will be enrolled to ensure sufficient 
subject s are comparable to the RGI-2001 treatment population.  
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 65 of 84 
12 STATISTICS  
The primary objective of this study is to assess the potential efficacy of RGI -2001. The primary 
endpoint for these purposes is grades II- IV acute GvHD, and the study subject s will be compared 
to a control group of subject s supplied by t he CIBMTR.  Control subjects will be chosen so as to 
meet all eligibility requirements for the clinical trial, have received a transplant in the same time 
window as the study subject s, and have been transplanted in a c enter that participates in this 
study.  
  
 
 
 
 
  
 
  
  
  
    
    
    
    
    
    
    
    
    
 
Based on these estimates, it is anticipated that a total of 50 subj ects who receive at least one dose 
of RGI -2001 will be enrolled , this including subject s from the run -in stage treated at  the dose 
moved forward to the Expansion Phase. It is anticipated th at a minimum of 250 subjects will be 
included in the control group.  
12.2 Demographics and Baseline Characteristics  
Categorical factors will be summarized with proportions, and continuous variables will be 
summarized using means and medians.  
12.3 Analysis Population, Handling of Dropouts, and Missing Data 
All subjects who receive at least one dose of RGI-2001 will be used for comparison to the 
CIBMTR subjects.   

Final Version  2.0 Proprietary and Confidential  06 March 2020  RGI-2001-003  Page 66  of 84 
12.3.1 Analysis of Efficacy Data  
The primary endpoint grades II- IV acute GvHD by D ay 100 according to the MAGIC criteria 
will be compared between the study group and CIBMTR controls using logistic regression. The 
factors that will be considered for adjustment in this model include  subject  age, gender, donor 
age, type of donor  (MRD, 8/8 UR D 7/8 URD) , source of allograft, diagnosis (AML, ALL, MDS, 
MPD  including CMML), preparative regimen , GvHD prophylaxis regimen . 
Secondary endpoints that will be modeled as binary outcomes will similarly be compared using 
logistic regression.  Secondary endpo ints that will be modeled a s time -to-event outcomes will be 
compared using Cox regression. 
Potent ial interactions of RGI-2001 and various factors will be examined by including appropriate 
factors into regression models.   
Given that this is not a randomized study and that the intention is  only to assess outcomes for a 
potential signal, no adjustments w ill be made for multiple comparisons.  As such, a Type II error 
(or a false negative) is prioritized over a Type I error (or a false positive).  
Binary exploratory outcomes will be summarized with proportions, continuous outcomes with 
means and medians, and time -to-event outcomes with Kaplan -Meier estimates or cumulative 
incidence estimates for endpoints with competing risks. 
12.4 Suspension R ules Based  on S afety  (RRT, Graft Failure, and NRM)  
Careful  monitoring  of safety w ill take pl ace b eyond  the Safety R un-in Pha se, with safety 
encompa
ssing the outcomes grade 4 -5 regimen- rated tox icity (RRT) , graft failure, and NRM.  
The st
udy will be suspended pending SRC review if there is s ufficient evidence to s uggest tha t 
the true f ailure rate for any of these outcomes is excessive. A  true g raft failure (as defined in 
Section 9.4.1 ) rate of 5
% or higher is considered excessive (Olsson e t al), a true Day-100 NRM 
rate o f 10 or  higher
 is cons idered exc essive  (Styczy ński et  al), and a true D ay 30 grade 4-5 RRT 
rate o f 50% or higher is considere d excessive (define d as any non- hematologic tox icity tha t 
occurs as
 a result o f
 the transplant pr ocess inc luding  the preparatory r egimen or  RGI - 2001 
infusions).  This ra te is extrapolated from  published re sults o f D30  NRM (Styczy ński et al )  and 
increased f urther to enc ompass grade  4 ev ents in t he allogeneic mye loablative  se tting based on 
site experience.  S ufficient  evidence w ill be  taken to be  a lower li mit to the  one- sided 80% 
confidence i
nterval asso ciated w ith an estimated failure rate that exceeds the  appropr iate l evel 
listed above.  Table 3 below show s observed outcomes that woul d trigger suspension, and 
Table 4 belo w summarizes the operating  characteristics of t he listed su spension  rule separately 
for each safety endpoint (e.g., separately for Day 30 grade 4-5 RRT, gra f t failure, D ay-100 
NRM).   
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 67 of 84 
Table 3 Suspension Rules for Grade 4 -5 RRT, Graft Failure, and Day-100 NRM  
Safety outcome  Occurrences that would trigger suspension rule and SRC review 
Day 30 grade 4-
5 RRT  3 RRT of first 3 pts, 4 RRT  of first 5 or fewer pts, 5/6, 6 /7-8, 7/9- 10, 8/11 -
12, 9/13, 10/14- 15, 11/16- 17, 12/18- 19, 13/20- 21, 14/22, 15/23- 24, 16/25-
26, 17/27- 28, 18/29- 30, 19/31- 32, 20/33- 34, 21/35, 22/36 -37, 23/38- 39, 
24/40-41, 25/42-43, 26/44-45, 27/46-47, 28/48-49, 29/50 
Graft Failure  2 failures of first 16  pts or fewer, 3/17 -30, 4/31-46, 5/47-50 
Day-100 NRM 2 failures of first 8 pts or fewer, 3/9 -15, 4/16- 23, 5/24- 31, 6/32 -39, 7/40- 47, 
8/48-50 
Table  4 Operating Characteristics of Suspension R ules 
Safety outcome  True probability  
of failure  Number of 
patients  Probability of suspension rule 
being triggered after listed 
number of patients  
Grade 4 -5 RRT  .30 10 
25 
45 .05 .05 
.10 
Grade 4 -5 RRT  .70 10 
25 45 .72 .94 .99 
Graft Failure  .02 10 
25 
45 .02 
.04 
.05 
Graft Failure  .12 10 
25 
45 .36 
.68 .88 
Day-100 NRM  .05 10 
25 45 .06 
.08 .08 
Day-100 NRM  .20 10 
25 
45 .51 
.78 .91 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 68 of 84 
13 ETHICAL AND ADMINISTRATIVE CONSIDERATIONS 
13.1 Ethics  
The procedures set out in this protocol, pertaining to the conduct, evaluation, and documentation 
of this study, are designed to ensure that the Sponsor and investigator abide by Good Clinical 
Practice (GCP) and International Conference on Harmonization  (ICH) guidelines. The study will 
also be carried out in keeping with applicable local laws and regulations. 
13.2 Compliance Sta tement  
This study will be conducted in accordance with the protocol and with GCP and ICH guidelines, 
as well as all applicable regulatory requirements. The investigator is responsible for ensuring that 
this protocol, the site’s informed consent form, and any other information that will be presented 
to potential subjects are reviewed and approved by the appropriate Institutional Review Board 
(IRB) prior to the enrollment of any study subject s. 
13.3 Institutional Review Board  
The investigator will submit this prot ocol, the informed consent, investigator’s brochure (IB), 
and any other relevant supporting information to the appropriate IRB and the local regulatory 
agency for review and approval prior to study initiation. A letter confirming IRB approval of the 
protocol and informed conse nt, a statement that the IRB  is organized and operates according to 
GCP and the applicable laws and regulations, and financial disclosures must be forwarded to the 
Sponsor prior to screening subject s for the study. 
Amendments to the protocol must also be approved by the IRB and the local regulatory agency, 
as appropriate, prior to the implementation of changes in this study. However, the investigator 
may implement a deviation from, or a change of, the protocol to eliminate an immediate 
hazard(s) to the study subject s without prior IRB/Sponsor approval/favorable opinion. As soon 
as possible, the implemented deviation or change, the reasons for it, and, if appropriate, the 
proposed protocol amendment, should be submitted to the IRB/Sponsor. Any deviations from the 
protocol must be fully explained and documented by the investigator. 
13.4 Informed Consent and Human Subject  Protection  
13.4.1 Direct Access to Source Data/Source Documents 
The study will be carried out in keeping with applicable local laws and regulations. This may 
include an inspection by Sponsor representatives/designees, and/or reg ulatory authority 
representatives at any time.  The investigator/institution must agree to the inspection of 
study- related records by the regulatory authority/ Sponsor representatives/designees, and must 
allow direct access to source documents to the regulat ory authority/Sponsor representatives/ 
designees/ IRB. The investigator must allocate time (investigator and study staff) to discuss 
findings and relevant issues with the regulatory authority/Sponsor representatives.  
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 69 of 84 
13.4.2 Data Quality Control and Quality Assuran ce: Data Handling and Recordkeeping 
Data collection will involve the use of the electronic data c apture  (EDC) system, to which only 
authorized personnel will have access.  Entries made on the electronic case report form (eCRF) 
must be verifiable against sou rce documents.  In addition to periodic monitoring occurring within 
the system by study monitors, programmatic edit checks and data listings will be used to revie w 
the data for completeness, logic, and adherence to study protocol. As a result of this monito ring 
and these checks, queries may be electronically issued to the clinical study sites and 
electronically resolved by those sites.  The identifying information (assigned username, date, and 
time) for both the originator of the query (if created during the monitoring and data reviewing 
process) and the originator of the data change (if applicable), as well as the PI’s approval of all changes performed on his/her su bject s’ data, will be collected.  
All data collected in the context of this study will be stored  and evaluated per regulatory 
requirements and applicable guidance for electronic records. Also, data will be stored and 
evaluated in such a way as to guarantee subject confidentiality in accordance with the legal stipulations applying to confidentiality of data.  Study records ( e.g., copies of eCRFs, regulatory 
documents) will be retained at the study site, along with adequate source documentation, according to FD A and ICH requirements.  The study file and all source data should be retained 
until written notification is given by the sponsor or designee for destruction. 
13.4.3 Confidentiality  
All records identifying the subject will be kept confidential and, to the extent p ermitted by the 
applicable laws and/or regulations, will not be made publicly available. 
Subject nam es will not be supplied to the S ponsor. Only the subject  number and initials  will be 
recorded on the case report form ( eCRF).  If the subject name appears on  any other document 
(e.g., pathologist report) or study materials (e.g., biopsy tiss ue slides), then that information must 
be deleted before a copy of the document is supplied to the sponsor. Study data stored on a 
computer will be stored in accordance wit h local data protection laws.  Subject s will be informed 
in writing that representatives of the sponsor, IRB, or regulatory authorities may inspect their 
medical records to verify the information collected, and that all personal information made 
available f or inspection will be handled in strictest confidence and in accordance with local d ata 
protection laws.  
If the results of the study are published, the subject ’s identity will remain confidential.  
The investigator will maintain a list to enable subjects’  records to be identified.  
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 70 of 84 
14 FINAL STUDY REPORT AND PUBLICATION POLICY  
A study report will be prepared by the Sponsor. Independent analysis and/or publication of these 
data by the investigator(s) or any member of their staff will comply with the terms of the clinical 
Trial Agreement between the Sponsor, and the investigational site and/or investigator.  
The Sponsor will comply with applicable laws regarding the requirements for publication of 
study results.  
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 71 of 84 
REFERENCES 
Brigl M, Brenner MB. CD1: antigen presentation and T cell function. Annu Rev Immunol. 
2004;22:817-890. PMID 1503259 
Brossay L, Chioda M, Burdin N, et al. CD1d-mediated recognition of an 
alphagalactosylceramide by natural killer T cells is highly conserved through mammalian 
evolution. J Exp Med. 1998;188:1521-1528. PMID 9782129 
Chen, Yi- Bin et al.  Increased Foxp3+Helios+ Regulatory T Cells and Decreased Acute Graft -
versus- Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving 
Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells . Biology of 
Blood and Marrow Transplantation , Volume 23 , Issue 4 , 625 - 634 
Duram ad O, Laysang A, Li J, Ishii Y, Namikawa R. Pharmacologic expansion of donor-derived, 
naturally occurring CD4+Foxp3 regulatory T cells reduces acute graft -versus-host 
disease lethality without abrogating the graft- versus -leukemia effect in murine models . 
Biol Blood Marro w Transplant 17: 1154-1168 (2011) 
Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, 
multicenter sta ndardization of acute graft-versus- host disease clinical data collection:  a 
report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow 
Transplant: J Am Soc Blood Marrow Transplant. 2016;22:4–10  
Ho VT, Soiffer RJ. The history and future of T- cell depletion as graft -versus- host disease 
prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood  2001;98(12):3192–204. PMID 11719354 
Ishida T, Harashima H, Kiwada H. Liposome clearance. Biosci Rep. 2002;22(2): 197-224. PMID 
12428901 
Ishii Y, Nozawa R, Takamoto-Matsui Y, Teng A, Katagiri- Matsumura H, Nishikawa H, et al. 
Alpha-galactosylceramide- driven immunotherapy for allergy. Front Biosci 
2008,13:6214–28. PMID 18508655 
Kawano T, Cui J, Koezuka Y, et al. CD1d- restricted and TC R-mediated activation of valpha14 
NKT cells by glycosylceramides. Science. 1997;278:1626-1629. PMID 9374463 
Magenau J, Qin X, Tawara I, Rogers C, Kitko C, Schlough M, Bickley D , Braun TM, Jang PS, 
Lowler KP , Jones DM, Choi SW, Reddy P, Mineishi S , Levine JE , Ferrara JL , Paczesny 
S. Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft -versus-host- disease. Biol Blood Marrow 
Transplant. 2010 16(7):907-14. PMID 20302964 
Moody DB, Zajonc DM, Wilson IA. Anatomy of CD1- lipid antigen complexes. Nat Rev  
Immunol. 2005;5:387-399. PMID 15864273 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 72 of 84 
Natori T, Koezuka, Y. & Higa, T. Agelasphins, novel α -galactosylceramides from the marine 
sponge Agelas mauritianus. Tetrahedron Lett. 1993;34:5591-5592. 
Olsson RF, Logan BR, Chaudhury S, Zhu X, et al. Primary graft failure after myeloablative 
allogeneic h ematopoietic c ell transplantation for hematologic m alignancies. Leukemia. 
2015 Aug; 29(8): 1754-1762. 
Paczesny S, Hanauer D, Sun Y and Reddy P. Bone Marrow Transplantation. 2010; 45: 1–11. 
PMID19946340 
Przepiorka  D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED. 1994 
Consensus Conference on Ac ute GVHD Grading. Bon e Marrow Transplant. 1995 
Jun;15(6):825- 8. 
Sagoo P, Lombardi G, Lechler RI. Regulatory T cells as therapeutic cells. Curr Opin Organ 
Transplant. 2008;13:645 -653. PMID 19060557 
Seltzer S, Shulkin P, Adams D, Davis M, Hoey G, Hopkins R, Bosworth M. Usefulness of 
Liposomes Carrying Losefamate for CT Opacification of Liver and Spleen. AJR 1984; 
143: 575-579. PMID 6331738 
Socié G, Blazar BR. Acute graft -versus- host disease: from the bench to the bedside. Blood 
2009;114(20):4327–36. PMID 19713461 
Styczy ński J, T ridello G, Koster L, Iacobelli S, et al. Death after hematopoietic stem cell 
transplantation: changes over calendar year time, infections and associated factors. Bone Marrow Transplant. 2020; 55:126-136. 
Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H. The regulatory role of Valpha14 NKT 
cells in innate and acquired immune response. Annu Rev Immunol. 2003;21:483-513. PMID 12543936 
Tupin E, Nicoletti A, Elhage R, Rudling M, Ljunggren HG, Hansson GK, et al.  
CD1d -dependent activation of NKT cells aggravates atherosclerosis. J Exp Med 
2004;199(3):417–22. PMID 14744994 
Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and 
autoimmunity. Nat Immunol. 2009;11:7-13. PMID 20016504 
Wolff D, Steiner B, Hildebrandt G, Edinger M, Holler E. Pharmaceutical and cellular strategies 
in prophylaxis and treatment of graft-versus-host disease. Curr Pharm Des. 2009;15(17):1974-97. PMID: 19519437 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 73 of 84 
15 APPENDICES  
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 74 of 84 
  
  
 
    
 
  
 
 
      
     
     
  
     
     
     
      
      
      
      
  
      
  
  
 
      
  
 
     
     
 
  
     
  
      
  
      
  
      
  
       
  
 

 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 75 of 84 
APPENDIX 2 MAGIC GVHD ASSESSMENT CRITERIA  
GvHD Target Organ Staging  
Stage  Skina Liver (bilirubin)  Upper GI  Lower G I  
(stool output/day)  
0 No active 
(erythematous) GvHD  
rash Total serum bilirubin  < 
34 umol/L (<  2 mg/dL)  No or intermittentb 
anorexia, nausea or 
vomiting  Diarrhea  <500mL  per day 
or <3 episodes/day for 
adults  c 
1 Maculopapular rash  < 
25% of BSA  Total serum bilirubin 34-50 umol/L (2  to 
3 mg/dL)  Persistent anorexia or nausea or  
vomiting  Diarrhea  500 - 999 mL per 
day or 3-4 episodes per 
day for adults  
c  
2 Maculopapular rash  
25 to 50% of BSA  Total serum bilirubin  
51-102umol/L ( 3.1 to 
6 mg/dL)   Diarrhea  1000–15 00 mL 
per day or 5 –7 episodes for 
adultsc 
3 Maculopapular rash  > 
50% of BSA  Total serum bilirubin 103-255 umol/L (6.1 to 
15 mg/d L)  Diarrhea  > 1500  mL per 
day or >  7 episodes for 
adults  
b 
4 Generalized  
erythroderma (>  50% 
BSA) plus  bullous  
formation and 
desquamation >  5% 
of BSA Total Serum bilirubin 
> 255umol/L 
(> 15 mg/dL)   Severe  abdominal  pain 
with or without ileus or 
grossly b loody stools 
(regardless of stool volume)  
c 
BSA: body surface area, GI: gastro -intestinal tract, GvHD: Graft versus Host Disease MAGIC: Mount Sinai Acute 
GvHD International Consortium  
 
Overall  Grade (based upon most  severe target organ involvement  
0 No stage 1 -4 of any organ 
I Stage 1 -2 skin without liver, upper GI or lower GI involvement  
II Stage 3 rash and/or stage 1 liver and/or stage 1 upper GI and/or stage 1 lower GI  
III Stage 2 -3 liver and/or stage 2 -3 lower GI, with stage 0 -3 skin and/or stage 0- 1 upper GI  
IV Stage 4 skin, liver, or lower GI involvement, with stage 0-1 upper GI  
a Use the “rule of nines” or burn chart to determine extent of rash  
b To be suggestive for GvHD: anorexia should be accompanied by weight loss, nausea should last at least 3 days, or be accompanied by at least 2 vomiting episodes per day for at lea st 2 days  
c One episode of diarrhea is considered to be about 200 ml for an adult and 3 ml/kg for a child (< 50 kg)  
 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 76 of 84 
Confidence Level Criteria  
Confidence 
Level  Pathologic 
Evidence  Clinician 
Assessment  Treatment for 
Acute GvHD  Comments  
Confirmed  Unequivocal 
pathologic 
evidence of GvHD  GvHD is the etiology 
for symptoms  Not applicable  GVHD is clearly present 
even if other etiologies  
may coexist simultaneously.  
Probable  Not required  GvHD most likely 
etiology for symptoms (as 
evidenced by 
treatment b eing 
provided)  Yes GVHD is most likely 
present, but other  
etiologies may also explain the  symptoms,  and 
there is insufficient evidence to make a  
confirmed diagnosis.  
Possible  Not required  GvHD in differential 
diagnosis (but no 
treatment is being 
provided)  No GVHD may be present, 
but other etiologies  are 
favored to the degree that GVHD 
treatme nt is not initiated.  
Negative  Unequivocal 
evidence of a diagnosis other than GvHD (e.g. drug rash  GvHD is no 
considered as an explanation for the symptoms  No and the 
symptoms resolve without GvHD treatment  GVHD may be present, 
but other etiologies  
are fav ored to the degree 
that GVHD  treatment is 
not initiated.  
 
Biopsy Results and Confidence Levels  
Pathology Results  Target Organ Confidence Level  
Treated as 
GvHD  Not treated but GvHD in 
Differential Diagnosis  Not Treated and GvHD Not in 
Differential Diagn osis 
Positive  Confirmed  Confirmed  Confirmed  
Equivocal Probable  Possible Possible 
Nondiagnostic  Probable  Possible Negative  
Non-GvHD etiology  Probable  Negative  Negative  
Source: Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate  U, et al. Intern ational, multicenter 
standardization of acute graft -versus -host disease clinical data collection: a report from the Mount Sinai Acute 
GVHD International Consortium. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 
2016;22:4- 10 
 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 77 of 84 
APPENDIX 3 MODIFIED KEYSTONE CRITERIA FOR ACUTE GVH D 
GvHD  Assessment  
Stage  Skina Liverb,c Gutc 
0 No GvHD rash Bilirubin  < 2 mg/dL  Diarrhea ≤ 500mL per  day No 
anorexia  or persistent  nausea  or 
anorexiad 
1 Rash  < 25% of skin Bilirubin  2 to 3 mg/dL  Diarrhea  > 500 mL per day or 
persistent  nausea or nausead 
2 Rash  25 to 50% of skin Bilirubin  3.1 to 6 mg/dL  Diarrhea ≥ 1000  mL per day 
3 Rash  > 50% of skin Bilirubin  6.1 to 15 mg/dL  Diarrhea ≥ 1500  mL per day 
4 Generalized  erythroderma  
with bullou s formation Bilirubin  > 15 mg/dL  Severe  abdominal  pain with or 
without ileus  
 
Overall  Gradee 
I Stage  1 to 2 None  None  
II Stage  3 or Stage  1 or Stage  1 
III – Stage  2 to 3 or Stage  2 to 4 
IVf Stage  4 or Stage  4 – 
a The Rules of Nines or burn chart  was us ed to determine  the extent  of rash. The percent  of body surface area 
involved with rash:  head  and neck (9%), right arm (9%), left arm (9%), anterior trunk  (18%),  posterior trunk  
(18%), right leg (18%),  left leg (18%), groin  and perineum  (1%).  
b Range  given a s total bilirubin.  
c For liver or gut, downgrade  1 stage  if additional  cause of elevated  bilirubin  or diarrhea  had been  documented.  
d Persistent  nausea or anorexia,  with histologic  evidence  of GvHD  in the stomach  or duodenum.  
e Criteria  for grading given as minimum  degree  of organ  involvement  required  to confer  that grade.  
f Grade  IV could  have  also included lesser  organ  involvement  but with extreme decrease  in performance  
Source: Przepiorka D, Weisdorf  D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED. 1994 Consensus 
Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995 Jun;15(6):825 -8. 
 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 78 of 84 
APPENDIX 4 NIH DEFINED DIAGNOSTIC OR DISTINCTIVE FEATURES OF 
CHRONIC GVHD 2 014  
Organ or 
Site Diagnostic  
(Sufficient to Establish the Diagnosis of Chronic 
GVHD)  Distinctivea  
(Seen in Chronic GVHD, but Insufficient Alone to 
Establish a Diagnosis)  Other Features  or 
Unclassified Entitiesb Commonc 
(Seen with Both Acute and Chronic 
GVHD) 
Skin Poikiloderma  
Lichen planus -like 
features  
Sclerotic  features  
Morphea -like features   
Lichen sclerosus -like 
features  Depigmentation  
Papulosquaous lesions  Sweat impairment  
Ichthyosis  
Keratosis pilaris  
Hypopigmentation  
Hyperpigmentation  Erythema  
Maculopapular rash  
Pruritus  
Nails   Dystrophy  
Longitudinal rid ging, 
splitting, or brittle features  
Onycholysis  
Pterygium unguis  
Nail loss (usually symmetric; 
affects most nails)    
Scalp and 
body hair   New onset of scarring or 
nonscarring scalp alopecia 
(after recovery from 
chemoradiotherapy)  
Loss of body hair,  
Scaling  Thinning scalp hair, 
typically patchy, coarse, 
or dull (not explained by 
endocrine or other causes)  
Premature gray hair   
Mouth  Lichen -type changes  Xerostomia  
Mucoceles 
Mucosal atrophy 
Ulcers  
Pseudomembranes   Gingivitis  
Mucositis  
Erythema  
Pain 
Eyes   New onset dry, gritty, or 
painful eyes  
Cicatricial conjunctivitis  
Keratoconjunctivitis sicca  
Confluent areas of punctate 
keratopathy  Photophobia  
Periorbital hyperpigmentation  
Blepharitis (erythema of 
the eyelids with edema)   
Genitalia  
  
Females  
 
Males  Lichen planus -like 
features  
Lichen sclerosus -like 
features  
Vaginal scarring or clitoral/labial 
agglutination  
Phimosis or 
urethral/meatus 
scarring or stenosis  Erosions  
Fissures Ulcers    
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 79 of 84 
Organ or 
Site Diagnostic  
(Sufficient to 
Establish the 
Diagnosis of Chronic 
GVHD)  Distinctivea  
(Seen in Chronic GVHD, but Insufficient Alone to 
Establish a Diagnosis)  Other Features  or 
Unclassified Entitiesb Commonc 
(Seen with Both Acute and Chronic 
GVHD) 
GI tract  Esophageal web  
Strictures or stenosis in the upper to mid third of the esophagus   Exocrine pancreatic 
insufficiency  Anorexia  
Nausea  
Vomiting  
Diarrhea  
Weight loss  
Failure to thrive 
(infants and 
children)  
Liver     Total bilirubin, 
alkaline phosphatase > 2 ULN  
ALT or AST 
> 2 ULN  
Lung  Bronchiolitis obliterans 
diagnosed with lung 
biopsy  BOSd Air trapping and b ronchiolitis 
obliterans on chest CT  Cryptogenic organizing 
pneumonia  
Restrictive lung diseasee  
Muscles, 
fascia, joints  Fasciitis  
Joint stiffness or contractures secondary 
to sclerosis  Myositis or polymyositisf Edema 
Muscle cramps  
Arthralgia or arthritis   
Hematopoie
tic and immune    Thrombocytopenia  
Eosinophilia  
Lymphopenia  
Hypo - or 
hypergammaglobulinemia  
Autoantibodies  
(AIHA and ITP)   
Other    Pericardial or pleural 
effusions  
Ascites  
Peripheral neuropathy  
Nephrotic syndrome  
Myasthenia gravis  
Cardiac conduction abnormality or 
cardiomyopathy   
GVHD indicates graft -versus -host disease; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AIHA, 
autoimmune hemolytic anemia; ITP, idiopathic thrombocytopenic pu rpura.  
a In all cases, infection, drug effects, malignancy, or other causes must be excluded.  
b Can be acknowledged as part of the chronic GvHD ma nifestations if diagnosis  is confirmed.  
c Common refers to shared features by both acute and chronic GVHD  
d BOS can be  diagnostic for lung chronic GVHD only if distinctive sign or s ymptom present in another organ  
e Pulmonary entities under investigation or unclassified.  
f Diagnosis of chronic GVHD requires biopsy.  
Source: Jagasia, Madan H. et al. National Institutes of Health  Consensus Development Project on Criteria for 
Clinical Trials in Chronic Graft -versus -Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. 
Biology of Blood and Marrow Transplantation, 2015 March; 21 (3):389– 401 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 80 of 84 
NIH Global Severity of Chronic GvHD  
Mild chronic GvHD  1 or 2 organs involved with no more than score 1 plus 
Lung score 0 
Moderate chronic GvHD 3 or more organs involved with no more than score 1  
OR 
At least 1 organ (not lung) with a score of 2  
OR 
Lung score 1 
Severe chronic GvHD  At least 1 organ with a score of 3  
OR 
Lung score of 2 or 3  
Key points:  In skin: higher of the two scores are to be used for calculating global 
severity.  
In lung: FEV1 is used instead of clinical score for calculating global severity.  
If the entire abnorma lity in an organ is note d to be unequivocally explained 
by a non- GvHD documented cause, that organ is not included for calculation 
of the global severity.  
In the abnormality in an organ is attributed to multifactorial causes (GvHD 
plus other causes) the sc ored organ will be used for calculation of the global 
severity regardless of the contributing causes (no downgrading of organ severity score).  
Source: Jagasia, Madan H. et al. National Institutes of Health Consensus Development Project on Criteria for 
Clinical Trials in Chronic Graft -versus -Host Disease: I. The 2014 Diagnosis and Staging Working Group Report . 
Biology of Blood and Marrow Transplantation, 2015 March; 21 (3):389– 401 
 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 81 of 84 
APPENDIX 5 KARNOFSKY PERFORMANCE STATUS SCORES  
Score (%) Karnofsky Performance Status  
100  Normal; no complaints;  no evidence of disease  
90  Able to carry on normal activity; minor signs or symptoms of disease  
80  Normal activity with effort ; some signs or symptoms of disease  
70  Cares for self; unable to  carry on normal activity or to do active work  
60  Requires occasional assistance, but is able to care for most personal needs  
50  Requires considerable assistance and frequent medical care  
40  Disabled;  requires special care and assistance  
30  Severely disabled;  hospital admission is indicated although death not imminent  
20  Very sick;  hospital admission necessary; active supportive treatment necessary  
10  Moribund; fatal processes progressing rapidly  
0  Dead  
Source: Karnofsky DA, Burchenal JH. (1949). "The Clinical Evaluation of Chemotherapeutic Agents in Cancer." In: 
MacLeod CM (Ed), Evaluation of Chemotherapeutic Agents. Columbia Univ Press. Page 196.   
 
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 82 of 84 
APPENDIX 6 CONTRACEPTIVE GUIDAN CE AND COLLECTION O F 
PREGNANCY INFORMATION  
Definitions:  
Woman of Childbearing Potential (WCBP) 
A woman is considered fertile following menarche and until becoming post -menopausal unless 
permanently sterile (see below)  
Women in the following categories are not considered WCB P: 
1. Premenarchal  
2. Premenopausal female with 1 of the following:  
• Documented hysterectomy  
• Documented bilateral salpingectomy  
• Documented bilateral oophorectomy  
3. Postmenopausal female  
• A postmenopausal state is defined as no menses for 12 months without an alterna tive 
medical cause. A high follicle stimulating hormone (FSH) level in the 
postmenopausal range may be used to confirm a postmenopausal state in women not 
using hormonal contraception or hormonal replacement therapy (HRT). However, in 
the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.  
• Females on HRT and whose menopausal status is in doubt will be required to use 1 of 
the non-estrogen hormonal highly effective contraception methods if they wish to 
continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment. 
Contracept ion Methods : 
Male patients  
• Are abstinent from penile -vaginal intercourse as their usual and preferred lifestyle 
(abstinent on a long term and persistent basis) and agree to remain abstinent 
• Agree to use a male condom plus partner use of a contraceptive method as described  
under highly effective contraceptive methods when having penile- vaginal intercourse 
with a woman of childbearing potential who is not currently pregnant. 
In addition, male patients must refrain from donating sperm for the duration of the study and for 3 months after the last dose of study treatment.  
Male patients with a pregnant or breastfeeding partner must agree to remain abstinent from penile- vaginal intercourse or use a male condom during each ep isode of penile penetration from 
the start of study treatment until 90 days after study treatment.  
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 83 of 84 
Female patients  
Female patients of childbearing potential are eligible to participate if they agree to use a highly 
effective method of contraception throughout the study and for 90 days after the end of study 
treatment.  
Highly effective methods include:  
• Combined (estrogen and progestogen containing) hormonal contraception associated 
with inhibition of ovulation 
− Oral  
− Intravaginal  
− Transdermal  
• Progestogen only hormonal contraception associated with inhibition of ovulation 
− Oral  
− Injectable  
− Implantable  
• Intrauterine device (IUD) 
• Intrauterine hormone -releasing system (IUS)  
• Bilateral tubal occlusion  
• Vasectomized partner  
• Sexual abstinence  
Pregnancy Testing:  
• WCBP must have a negative serum pregnancy test prior to initiation of study drug. 
Pregnancy Reporting Guid elines : 
Although pregnancy is not considered an AE or SAE, all pregnancies occurring in subjects 
enrolled in this study or in a fem ale partner of a male subject in this study must be reported to the 
Sponsor on an expedited basis and followed to outcome, even after the end of the study.  
If a female subject inadvertently beco mes pregnant while on study treatment, the subject will 
immed iately be removed from the study. Any pregnancies that occur within 150 days for females 
or 90 days for males following the last dose of study treatment must be reported to the Sponsor.  The inve stigator should report all pregnancies in clinical trial to the Sponsor within 24 hours of 
becoming aware. A Pregnancy Report Form must be completed and submitted to the Medical 
Monitor. If the pregnancy has occurred in the female partner of a male subject , the investigator 
should attempt to collect pregnancy information after obtaining the necessary signed ICF from the pregnant female partner directly .  
 
 
Final Version  2.0 Proprietary and Confidential  06 March 2020   
 
  
RGI-2001-003   
Page 84 of 84 
The outcome of the pregnancy should be reported on a separate Pregnancy Outcome Report 
Form.  
Some complications of the pregnancy may constitute an SA E. Those include spontaneous and 
elective abortion, premature delivery, congenital anomaly or birth defect in an offspring , death of 
a newborn within 28 days of birth. In these cases, a separate SAE R eport Form should be filled 
in and submitted on an offsp ring, along with the Pregnancy Outcome Report Form on the 
mother.  